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1. Literature Review and Introduction 
1.1. The peroxisome structure, functions and biogenesis  
1.1.1. Basic morphology and metabolic function of peroxisomes 
Peroxisomes are a diverse group of organelles which accommodate many 
activities related to lipid metabolism. The morphology of peroxisomes differs 
significantly among various tissues and species. The size, abundance and 
enzyme content of peroxisomes can be affected by various environmental, 
metabolic, and developmental factors. In typical human cells peroxisomes are 
mostly spherical and their diameter ranges from 0.2 μm to1 μm. In oleate grown 
yeast their size is approximately 0.5 m, whereas they tend to be significantly 
smaller in yeast grown on glucose containing medium (0.1-0.2 m). The basic 
structure of peroxisomes consists of a lipid bilayer surrounding a fine granular 
protein matrix core with a crystalline (urate oxidase) in some species (see figure 
1). The occurrence of tubular structures has been reported in several organisms, 
some seeming to interconnect the spherical compartments (Baumgart, 1997; 
Yamamoto and Fahimi, 1987). 
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Figure.1. Schematic representation of the basic structure the peroxisome: mainly 
consist of a surrounding lipid bilayer and a fine granular matrix with a crystalline 
core of urate oxidase in rodeuts. PMP = peroxisome membrane protein (e.g. 
substrate transporters)  
Peroxisomes have been reported to have a very electron dense matrix with a 
paracrystalline structures core of urate oxidase or margiual plates made of α-
hydroxyacid oxidase B (Angermüller et al., 1986; Baumgart, 1997; Zaar et al., 
1986). The Woronin body of the filamentous fungi Neurospora crassa is a new 
type of specialized peroxisome which contains a hexagonal crystalloid core and 
appears to obstruct septal pores of the syncytium upon cellular damage (Jedd 
and Chua, 2000). 
Peroxisomes were thought to arise de novo, nowadays thought to be built 
directly(Hettema et al., 2014) or multiply by fission of preexisting peroxisomes 
(Anthonio et al., 2009). The relative contribution of both pathways to the total 
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number of peroxisomes in wild type cells is not yet clear. Furthermore, the 
molecular mechanisms governing these processes are only beginning to be 
unraveled (Anthonio et al., 2009). 
As an important functional ubiquitous cell organelle, the peroxisomes play 
important roles in a variety of metabolic processes, which are as widespread as 
their morphologies throughout the eukaryotic kingdom. These can be listed as:  
a) The metabolism of hydrogen peroxide: Hydrogen peroxide (H2O2) 
respiration is a well-conserved function throughout all peroxisomal 
metabolic tasks. In particular a variety of peroxisomal oxidases produce 
H2O2 as byproduct during the oxidation of their substrates and Catalase 
degrades the toxic H2O2 within the peroxisomal matrix. 
b) Degradation of toxic or bioactive lipid derivatives, such as bile acid 
intermediates phytanic acid and eicosanoids: Peroxisomes exert 
complementary functions to mitochondria by degradation of fatty acids. 
Further peroxisomes can comprise the β-oxidative degradation of a 
specific set of lipids which cannot be processed by mitochondria, such as 
the very long chain fatty acids (VLCFA), long chain dicarboxylic acids, 
various unsaturated fatty acids, di- and trihydroxycholestanoic acids and 
pristanoic acid and eicosanoids (prostaglandins and leukotrienes). 
c) Synthesis of membrane lipids like cholesterol, the biogenesis of etherlipids 
(e.g.plasmalogens) and ester-phospholipids (glycerolphospholipids): 
peroxisome associate with the smooth Endoplasmic Reticulum (ER), since 
plasmalogens are synthesized cooperatively in the ER and the 
peroxisome, with the peroxisome being the site of introduction of the ether 
linkage into the plasmalogens. While the precise role of the plasmalogens 
is not clear, probably ROS trapping or regulation of physical membrane 
properties (Karnati and Baumgart-Vogt, 2008), severe pathological 
consequences of a deficiency in the plasmalogen synthesis hint at a 
central role in the human organism (Eckert and Erdmann, 2003). 
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Since peroxisomes have various biological and metabolic functions their 
abundance and their enzyme composition in distinct cell types, tissues or organs 
is very heterogenous, depending on the specific metabolic pathway (Baumgart, 
1997). Up to now, a lot of effort has been invested into determining the functional 
properties of peroxisomes in humans. Human peroxisome do not contain urate 
oxidase core since the appropriate gene carries a mutation deleting this enzyme 
(Alvares et al., 1992). Human peroxisomes harbour most often pathway 
mentioned above and take part in the de novo synthesis of cholesterol from 
different precursor molecules and play a major role in isoprenoid metabolism 
(Biardi et al., 1994; Krisans, 1992; Krisans et al., 1994) Furthermore, the 
glyoxylate aminotransferase, which transforms toxic glyoxylate into alanine, is 
localized in the peroxisome (Noguchi and Fujiwara, 1988). 
1.1.2. Peroxisome biogenesis  
1.1.2.1. Basic routine of peroxisome formation 
Peroxisome biogenesis describes the combination of processes which are 
involved in the formation of the peroxisomal membrane, the import of proteins 
into the peroxisomal matrix and the proliferation of the peroxisomes. Combined 
genetic and biochemical approaches lead to the identification of more than 30 
Pex genes which encode proteins required for the biogenesis of peroxisomes, 
named peroxins “PEX proteins = PEX ….” (Distel et al., 1996; Smith and 
Aitchison, 2009). The proxins have got their number according to their date of 
discovery, independent of their function in peroxisome biogenesis and cellular 
location. 
Two of the most important components of the peroxisome are the matrix and the 
membrane proteins which are synthesized by ribosomes in the cytosol and are 
then imported into the peroxisome. Whereby the machineries to perform the 
protein import, targeting and insertion of peroxisomal membrane proteins are 
completely different (Eckert and Erdmann, 2003).  
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The roles of several groups of peroxins are distinctly different. In particular PEX3, 
PEX16 and PEX19 of the peroxisomal membrane have been found to play 
particular roles. Human cells lacking one of these peroxins neither have 
peroxisomes nor peroxisomal remnants (Ghaedi et al., 2000; Honsho et al., 1998; 
Matsuzono et al., 1999; Sacksteder et al., 2000; Shimozawa et al., 2000; South 
and Gould, 1999). In contrast deletions of any of the other peroxins result in the 
presence of “ghost” peroxisomal structures with a spherical membranous 
structure containing several peroxisomal membrane proteins. (Eckert and 
Erdmann, 2003). To sum up, all peroxins and their roles in the biogenesis of 
peroxisomes can be classified according to different processes of peroxisome 
formation. Peroxins involved in the formation of peroxisomal membrane, the 
import of matrix proteins, peroxins controlling peroxisome size and abundance 
and peroxisome inheritance (see Table.1.) (Smith and Aitchison, 2009). 
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Table.1. The summary of proteins and corresponding functions involved in peroxisome in the model of Yeast. Table 
adjusted according to (Fransen et al., 2002; Smith and Aitchison, 2009). 
Proteins involved in formation of peroxisomes and pre-peroxisomal vesicles from the ER Proteins involved in import of matrix proteins 
Pex3p Membrane receptor for PMP recruitment lipid binding protein  Pex1p# AAA ATPase; PMP 
Pex16p PMP that traffics through the ER; membrane receptor for PMP recruitment in 
mammalian cells 
Pex2p# PMP; RING finger protein 
Pex19p# 
 
PMP chaperone and transporter; farnesylated and mostly cytosolic 
 
Pex4p PMP anchored by Pex22p; ubiquitin-conjugating enzyme involved 
in receptor recycling 
Proteins involved in controlling peroxisome size and number Pex5p# PTS1 receptor; predominantly cytoplasmic 
Pex11p# Integral PMP involved peroxisomal fission and proliferation 
(Li et al., 2002a) 
Pex6p# AAA ATPase; PMP 
Pex25p Peripheral PMP; interacts with paralog Pex27p; recruits Rho1p to peroxisomes Pex7p# PTS2 receptor; predominantly cytoplasmic 
Pex27p interacts with paralog Pex25p Pex8p Intraperoxisomal PMP; links docking and RING finger complex 
Pex28p 
/Pex24p 
PMP known as Pex28p in S. cerevisiae and Pex24p in Y. lipolytica. Pex10p# PMP; RING finger protein; E3 ligase for Ubc4p dependent 
ubiquitination of Pex5p 
Pex29p PMP with yet unkown functions Pex12p# PMP; RING finger protein 
Pex30p/ 
Pex23p 
PMP; known as Pex30p in  S. cerevisiaeand Pex23p in  Y. lipolytica; contains a 
dysferlin domain; partially functionally redundant with Pex31p and Pex32p 
Pex13p# PMP; docking complex component 
Pex31p 
 
PMP; contains dysferlin domain 
 
Pex14p# PMP; docking complex component 
Pex32p PMP; contains dysferlin domain Pex15p/ 
Pex26p 
functional homologs in yeast and mammals, respectively; PMP 
involved in membrane anchor of Pex6p  
DRPs# Dynamin-related proteins includeVps1p and Dnm1p in yeast and Dlp1p in 
mammalian cells 
Pex17p PMP; docking complex component 
Fis1p/Mdv1
p/Caf4p 
DRP recruitment to peroxisomes Pex20p Co-receptor required for Pex7p binding cargo; Saccharomyces 
cerevisiae has functional homologs Pex21p/Pex18p instead  
Rho1p Guanosine triphosphatase involved in actin assembly on peroxisomes; interacts 
with Pex25p and Pex30p 
Pex22p PMP that anchors Pex4p to the membrane  
 Cytosolic 
chaperones 
Chaperones including members of Hsp70 family and DnaJ-like 
proteins may be involved in import 
Proteins involved in peroxisome inheritance 
Inp1 PMP involved in retention of peroxisomes in mother and daughter cells by attaching peroxisomes to cell cortex 
Inp2 PMP involved in peroxisome movement through interaction with Myo2  Myo2p Motor that propels peroxisomes along actin cables 
# PMP, peroxisomal membrane protein; peroxins are known to have similar roles in yeast and in higher eukaryotes. 
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A model to demonstrate how peroxisomes might be generated was established 
based on the latest literature. The principle was hypothesized which comprises 
two ways as following: Peroxisomes arise de novo or multiply by fission of 
preexisting peroxisomes(Hettema et al., 2014).  
The hypothesized route of peroxisome biogenesis begins with a preperoxisomal 
membrane vesicle originating from an endomembrane which can be understood 
as the ER or a “peroxisomal pre-structure” that could act as a template for the 
growing and maturing organelle and could already contain the pioneer peroxins 
such as Pex3p or Pex15p (Eckert and Erdmann, 2003). Further, peroxisome 
membrane proteins (PMP) could be incorporated for later process and the last 
step to complete the peroxisome maturation process could be import of 
peroxisomal matrix proteins into the matured peroxisomal membrane (Eckert and 
Erdmann, 2003; Hettema et al., 2014). The way of peroxisome formation could 
be also based on the growth and division model which suggested that the 
posttranslational import of matrix and membrane proteins into presenting 
peroxisomes could be followed by the proliferation of peroxisomes(Lazarow and 
Fujiki, 1985). This hypothesis described the generation of new peroxisomes by 
presenting mature peroxisomes or could be also by the “peroxisomal pre-
structure” growing through a continuous import of PMPs and matrix proteins and 
a final division. This process is possibly controlled directly or indirectly by Pex11p. 
(Eckert and Erdmann, 2003; Li et al., 2002a; Schrader et al., 2012)  
It was assumed that these two routes could occur simultaneously in peroxisome 
biogenesis (Figure.2.). The fractions of each route’s contribution to the overall 
peroxisome biogenesis are still unknown. 
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Figure.2. Schematic representation of the two-way model of peroxisome 
biogenesis in Yeast model. The graph was modified from (Eckert and Erdmann, 
2003).  
 
Second way of Peroxisome Biogenesis 
First way of Peroxisome 
Biogenesis 
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1.1.2.2. Topogenesis of peroxisomal membrane proteins 
Within different processes of peroxisome biogenesis, the PMPs import pathway 
has very unique features. It has been believed that the most PMPs can post-
translationally target the peroxisome directly from the cytosol. In this respect 
peroxin Pex19p plays an essential role as a master transporter in the 
translocation process (Diestelkotter and Just, 1993; Imanaka et al., 1996; Pause 
et al., 2000; van der Zand et al., 2006). 
Since the participation of the Pex19p is critical in the topogenesis of peroxisomal 
membrane proteins, Eckert and Erdmann summarized that all PMPs can be 
classified into three types (I-III) according to their translocation process (Figure.3.) 
 
Figure.3. Model of branched pathways for the topogenesis of peroxisomal 
membrane proteins in Yeast model (Eckert and Erdmann, 2003). 
The type I PMPs, such as newly formed PMP34, PMP47 and Pex11p, can be 
recognized directly and guided to the peroxisomal membrane docking site via 
signaling effect of Pex19p. It has been presumed that the Pex3p may contribute 
to the insertion of type I PMP after the PMP translocation has been achieved 
(Eckert and Erdmann, 2003). 
Type II PMPs can be bound by cytosolic Pex19p to form a complex and this 
complex can be directed and transported to the peroxisomal membrane with the 
14 
 
contribution of Pex19p. Pex19p actually acts as a “chaperone” in this type of 
PMP translocation process (van der Zand et al., 2006). In the further process, the 
membrane-integrated Pex3p may contribute to PMPs membrane targeting by 
recruiting this complex to the peroxisomal membrane. The translocation process 
is completed through the release of PMPs from the complex and the released 
PMPs are inserted into the membrane(Eckert and Erdmann, 2003). 
Therefore, the transport system for type II PMPs comprises of cytosolic Pex19p 
and membrane-spanning protein Pex3p. The translocation of type II PMPs into 
peroxisomal membranes is depicted in Figure.4. 
 
 
 
Figure.4. Model for the roles of Pex3p and Pex19p play in the insertion of PMPs 
into the peroxisomal membrane (van der Zand et al., 2006). 
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It has been assumed that the formation of the peroxisome initiates insertion of 
Pex3p into to membrane of the ER. The following step is that Pex19p is recruited 
to the membrane, resulting in the formation of the “peroxisomal pre-structure”. In 
the cytosol, the Pex19p is continuously involved in the PMPs import by binding 
PMPs and targeting them to this “pre-peroxisomal” membrane to accomplish 
peroxisome membrane formation (Eckert and Erdmann, 2003; Hettema et al., 
2014). The functional maturation of the “peroxisomal pre-structure” to a 
peroxisome is achieved with the import of peroxisomal matrix proteins which 
starts after the completion of the insertion of the PMPs (Eckert and Erdmann, 
2003).  
The type III PMPs are comprised of early peroxins which are proposed to 
efficiently target peroxisomes or the “peroxisomal pre-structure” completely 
independent of Pex19p and Pex3p (Eckert and Erdmann, 2003). 
1.1.2.3. Import of peroxisomal matrix proteins 
The peroxisomal import machinery accepts folded proteins, oligomerized proteins, 
and items of large diameter such as gold particles fused to import signals as 
substrates (McNew and Goodman, 1994; Walton et al., 1995). Most of the 
peroxisomal proteins are equipped with distinct peroxisomal targeting signals 
(PTS) which consists of both of PTS1 located in protein carboxyl-terminal with 
consensus sequence (S/C/A) (K/R/H) (L/M) and PTS2 located in protein amino-
terminus with the consensus sequence (R/K)(L/V/I)(X)5(H/Q)(L/A)(Gould et al., 
1989; Rachubinski and Subramani, 1995; Rehling et al., 1996; Swinkels et al., 
1991). The PTS sufficiently enables peroxisomal matrix proteins to be recognized 
and guided from the cytosol into the peroxisomal matrix (Subramani, 1993; 
Wanders, 2004a). 
The “shuttling receptor” model of the mechanism for peroxisomal matrix protein 
translocation has mostly been supported by the latest literature. The 
predominantly in the cytosol localized proteins Pex5p and Pex7p can individually 
or simultaneously be recognized, either one or two PTS (Pex5p can recognize 
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PTS1 and PEX7 can recognize PTS2), which have been harbored in the cytosol 
formed peroxisomal matrix protein (Dammai and Subramani, 2001; Ghys et al., 
2002; Girzalsky et al., 2009; Mukai et al., 2002).Therefore in this model, the 
Pex5p and Pex7p can be recognized as “PTS receptors” and the peroxisomal 
matrix protein can recognize it as “cargo” protein. The whole process of this 
mechanism can be divided into 3 steps. Figure.5. displays the complete 
translocation machinery for peroxisomal matrix proteins from the cytosol to the 
peroxisomal matrix. 
 
 
Figure.5. Model of the peroxisomal protein import cascade (Eckert and Erdmann, 
2003). 
Step 1 - recognition and translocation: This step is the starting event to initiate 
the peroxisome matrix protein import cascade. The cargo protein can be 
recognized and bound by PTS receptors, in particular Pex5p and Pex7p, to form 
an import competent complex the cytosol, followed by the transportation of this 
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complex to the peroxisomal membrane where common docking and translocation 
complexes are available for the next step. 
Step 2 - peroxisomal membrane docking: The peroxisomal membrane docking 
system mainly comprises 3 types of peroxisome transmembrane proteins, 
Pex13p, Pex14p and Pex17p which are featured with Pex5p and Pex7p binding 
sites (Albertini et al., 1997). Pex13p is a peroxisomal integral membrane protein 
which plays a direct role in both PTS1 and PTS2 protein import, or indirectly 
prevents matrix protein import by disrupting peroxisomal membrane formation, in 
particular, Pex13p is a transmembrane protein which exposes both termini to the 
cytosol. The N-terminal domain has been shown to provide the binding site for 
Pex7p (Albertini et al., 1997; Stein et al., 2002). Pex5p and Pex14p bind to the C-
terminal Src homologe (SH3) domain of Pex13p (Gould et al., 1996). A typical 
proline-rich SH3-ligand motif in Pex14p is responsible for the binding to the SH3 
domain of Pex13p (Girzalsky et al., 1999; Pires et al., 2003). 
Step 3 - dissociation, translocation and lumen releasing: The “receptor-cargo” 
complex can dissociate from the peroxisomal membrane docking system, 
followed by the “cargo” protein being released from the “receptor-cargo” complex 
into the peroxisomal lumen to complete the whole peroxisomal matrix 
translocation process. 
After the dissociation from the complex, the “PTS receptor” proteins Pex5p and 
Pex7p are destined to be recycled and brought back to the cytosol thus they can 
be re-used in further translocation cycles. 
1.1.2.4. Peroxisome proliferation 
Up to now, the mechanism of peroxisome growth and division processes is still 
not understood. Several genes have been suggested to be involved in 
peroxisome proliferation. In particular, the dynamin-like protein DLP1 and 
dynamin-related protein Vps1p, both of which belong to the dynamin family of 
large GTPases, whose function have been understood as involving in tubulation 
and fission events of cellular membranes (Danino and Hinshaw, 2001; McNiven, 
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1998). The dynamin-like protein (DLP1) has been found required for peroxisome 
fission process in mammalian cells (Koch et al., 2003; Li and Gould, 2003) and 
further the functional domain of DLP1 has been identified to be responsible for 
this requirement because the expression of a dominant-negative DLP1 mutant 
deficient in GTP hydrolysis (K38A) inhibited peroxisomal division (Koch et al., 
2003). The dynamin-related protein Vps1p mediates peroxisome division in 
Saccharomyces cerevisiae (Hoepfner et al., 2001). The general understanding of 
peroxisome proliferation, which has been mostly accepted, is that the replication 
of peroxisomes starts from pre-existing peroxisomes fission to form new ones, 
coordinated by Pex11p (Li and Gould, 2002). 
Amoung the genes or proteins which were suggested to have critical functions for 
peroxisome proliferation, only Pex11p has been generally and dominantly 
accepted to have conserved functions for peroxisome proliferation and implicated 
in the regulation of peroxisome growth in size and abundance (Erdmann and 
Blobel, 1995; Li et al., 2002a; Li and Gould, 2002; Marshall et al., 1995; 
Passreiter et al., 1998; Schrader et al., 1998).This mechanism has been 
supported by the experiments in which peroxisome elongation and vice-versa 
that subsequent division has been induced by Pex11 gene overexpression and 
the peroxisome abundance decrease by the reduction of Pex11 gene expression 
(Li et al., 2002b; Marshall et al., 1995; Schrader et al., 1998). The PEX11 
proteins exist universally in peroxisomal membranes from yeast, protozoan, 
parasites to mammal cells. Within them the Pex11 genes in mammals have been 
very well investigated and characterized, including three different isoforms, 
PEX11α, β and γ (Li et al., 2002a; Li et al., 2002b). 
The constructive isoform PEX11β can promote peroxisome proliferation in the 
absence of extracellular stimuli in human and rat cells (Schrader et al., 1998),and 
Pex11β has currently been connected to mechanisms regulating peroxisome 
proliferation, by which the PEX11β protein plays the role of a coordinator to 
recruit DLP1 to the peroxisome membrane position where the DLP1 functions as 
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a ‘pinchase’ to release the newly formed daughter organelles(Kozlov, 1999). 
Thereafter the PEX11β protein is separated from DPL1 (Li and Gould, 2003). 
However, the roles of these 3 PEX11 Protein isoforms in the peroxisome 
proliferation process are very different and most of the details of the mechanisms 
on how these genes regulate peroxisome proliferation are still not understood. 
Even some phenomenons which have been observed are still not understood. 
There are two typical examples. One phenomenon that has been observed is 
that PEX11α can regulate peroxisome abundance in response to extracellular 
stimulation of peroxisome proliferator clofibrate and di-(2-ethylhexyl)-phthalate 
(Passreiter et al., 1998). In contrast, peroxisome proliferation also occurs in the 
liver of PEX11α knockout (KO) mice after treatment with both of these drugs (Li 
et al., 2002a). The second example is that it has been suggested that PEX11β 
may be involved in the elongation/tubulation of peroxisomes, while DLP1 should 
mediate peroxisome fission (Koch et al., 2004). In contrast, clusters of elongated 
tubular peroxisomes have been found on the ultrastructural level in the liver of 
Pex11β KO mice (Li et al., 2002b). 
1.1.3. Enzyme composition and metabolic functions in peroxisomes 
1.1.3.1. β-oxidation of fatty acids and fatty acid derivatives in peroxisomes 
One of the most important functions of peroxisomes is the catabolism of fatty 
acids and fatty acid derivatives via β-oxidation in plant (Cooper and Beevers, 
1969) and animal cells (Lazarow and De Duve, 1976). This process has been 
studied for more than 40 years. The β-oxidation can basically be understood as a 
cyclic process by which fatty acids are degraded from their COOH- terminal end. 
In each cycle the fatty acid carbon chain are shortened with two carbon atoms 
and one acetyl-CoA being released. The released acetyl-CoA unit can then be 
degraded in the citric acid cycle to produce CO2 and H2O. When comparing the 
β-oxidation enzymes in different species such as Homo sapiens, Mus musculus 
and Rattus norvegicus certain enzymes can be found: acyl-CoA oxidase (ACOX), 
DBP (D-bifunctional enzyme), LBP (L-bifunctional enzyme), SCPx (sterol carrier 
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protein X), thiolase A, thiolase B (Baumgart et al., 1996a; Baumgart et al., 1996b; 
Dieuaide-Noubhani et al., 1996). The enzymes involved in the peroxisomal β-
oxidation vary depending on the types of fatty acids and different species (Figure. 
6.), possess different substrates specificity and vary between species, organs, 
tissues and cell types (Baumgart, 1997).  
Generally, the structural understanding of the peroxisomal β-oxidation system for 
an acyl-CoA ester is comparable to that of mitochondria and consists of four 
subsequent steps: (I) oxidation to a 2-trans-enoyl-CoA compound 
(dehydrogenation in mitochondria), (II) hydration of the double bond, (III) a further 
dehydrogenation and (IV) thiolytic cleavage (Wanders et al., 2010). In 
peroxisomes, step I is catalyzed by acyl-CoA oxidases producing H2O2 during 
substrate conversion. In contrast the first step of the β-oxidation in mitochondria 
is catalyzed by acyl-CoA dehydrogenases (ACADs). 
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Figure.6. The enzymes involved in each step of the peroxisomal β-oxidation 
depend on which compound the enzyme reacts with and the different species. The 
graph was modified from (Visser et al., 2007). 
Three types of ACOX enzymes have been discovered in mammals and have 
been found to work on different targets. ACOX1, also named Palmitoyl-CoA 
oxidase, is specific for straight-chain fatty acids such as VLCFA and eicosanoids 
(Baumgart et al., 1996b). The ACOX2 and ACOX3, also named 
trihydroxycoprostanoyl-CoA oxidase and pristanoyl-CoA oxidase, specifically 
react with the CoA-esters of bile acid intermediates and 2-methyl branched-chain 
fatty acids, such as pristanoyl-CoA (Baumgart et al., 1996a).  
In comparison to rodents, the human gene of ACOX3 which is expressed at very 
low level is not functional, whereas the mRNA and proteins level of the ACOX1 
and ACOX2 genes are expressed similarly in rodents and man. In humans 
ACOX2 is involved in the degradation of pristanic acid and bile acid (Vanhooren 
et al., 1997), dihydroxycholestanoic acid (DHCA) and trihydroxycholestanoic acid 
(THCA), which is 3-methyl-branched fatty acids and bile acid intermediates 
(Figure 7) (Baumgart et al., 1996a). 
22 
 
 
Figure.7. Enzymology of the peroxisomal β-oxidation systems involved in the 
oxidation of pristanic acid, VLCFA and DHCA/THCA in human (Wanders et al., 
2010). 
The peroxisomal β-oxidation steps II and III, the hydration of the double bond and 
the dehydrogenation are carried out by multifunctional proteins (MFPs). The 
enzymatic activity of enoyl-CoA hydratase and 3-hydroxyacyl-CoA 
dehydrogenase, by which the enoyl-CoA-esters of VLCFA, pristanic acid, DHCA, 
and THCA are further metabolized depend on the structure of the fatty acids. 
Two types of MFPs have been discovered in peroxisomes, such as the MFP2 for 
pristanic acid and the bile acid intermediates which contain a 2-methyl branch in 
the carbon chain, whereas the substrates with a straight carbon chain can react 
universally with both MFP1 and MFP2 (Dieuaide-Noubhani et al., 1997; Van 
Veldhoven).  
Depending on the substrate, two types of enzymes are involved in the step IV of 
thiolytic cleavage in peroxisomal β-oxidation. (Figure. 7.) The first type of enzyme 
was found to be involved in the thiolytic cleavage in the liver of rats. Thiolase A 
and Thiolase B that can act on straight chain ketoacyl-CoAs (Hijikata et al., 1990). 
The second type of enzyme is the sterol carrier protein X (SCPx) which has 
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much broader substrates specificity. It catalyzes the cleavage of both straight 
chain and 2-methyl ketoacyl-CoAs due to its thiolase activity (Antonenkov et al., 
1997). In particular, SCPx can react with the 3-keto-acyl-CoA-esters of pristanic 
acid, DHCA and THCA during peroxisomal β-oxidation (Figure.7.) (Seedorf et al., 
1994). 
1.1.3.2. The etherphospholipid synthesis in peroxisomes 
The biogenesis of etherphospholipids is processed successively in peroxisomes 
and the ER. The synthesis consists of three steps. The first two steps take place 
in the peroxisome and are catalyzed by peroxisomal enzymes (Singh et al., 1989; 
Wanders, 2004b). The first Step: the compound dihydroxyacetonephosphate 
(DHAP), now named glyceronephosphate (GNP), is converted to acyl-DHAP. 
This step is catalyzed by the dihydroxyacetone phosphate acyltransferase 
(DHAPAT or GNPAT). During the second step this product is further converted to 
alkyl-DHAP, which is catalyzed by alkyldihydroxyacetone phosphate synthase 
(ADHAPS or AGPS) (Wanders, 2004b). The last step takes place both in the 
peroxisome and the ER and contains the production of alkylglycerol-3-phosphate 
(alkyl-G-3P). This step is catalyzed by the enzyme alkyl/acyl-DHAP NAD(P)H 
oxidoreductase. At the end of the third step the further conversion to plasmogens 
takes place in the ER (Brites et al., 2004).  
The importance of etherphspholipids for cell survival lies in their contribution to 
biophysical properties of cell membranes. Moreover, etherphospholipids can trap 
ROS molecules to protect the cell membrane against damage caused by lipid 
peroxidation (Karnati and Baumgart-Vogt, 2008). One important feature of 
etherphospholipids is the vinyl ether bond which is especially important for ROS 
trapping (Brites et al., 2004). Two peroxisomal enzymes DHAPAT (or GNPAT) 
and ADHAPS (or AGPS) are known to be crucial for etherphospholipid 
biosynthesis. Brites et al. have determined that patients with deficiencies of either 
DHAPAT(GNPAT) or ADHAPS(AGPS) lack the etherphospholipid synthesis 
(Brites et al., 2004).  
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1.1.3.3. The cholesterol synthesis in peroxisomes 
Peroxisomes play a major role in isoprenoid and cholesterol biosynthesis. This 
fact underlines the importance of this organelle for cells. Especially cholesterol is 
very abundant in lipid rafts, harboring various functionally different signaling 
receptors.  
There are three strong reasons to recognize that peroxisomes are essential and 
major cell organelles for the synthesis of isoprenoid and cholesterol. Firstly, 
acetyl-CoA derived from peroxisomal β-oxidation of very long-chain fatty acids 
and medium-chain dicarboxylic acids is preferentially channeled to cholesterol 
synthesis inside the peroxisomes (Kovacs et al., 2007). Secondly, peroxisomal 
enzymes, in particular the isopentenyl diphosphate delta isomerase (IDI1), 
mevalonate kinase (MVK), phosphomevalonate kinase (PMVK) and mevalonate 
pyrophosphate decarboxylase (MPD), can catalyze conversion of mevalonate to 
farnesyl diphosphate (FPP), which is an essential step for isoprenoid and 
cholesterol synthesis. The conversion of FPP to lanosterol is believed to occur in 
the ER (Kovacs et al., 2002; Kovacs et al., 2007). Last but not least, the literature 
also reveals that peroxisomes play a vital role in the maintenance of cholesterol 
homeostasis (Kovacs et al., 2004).  
1.1.3.4. Metabolism of reactive oxygen and nitrogen species in 
peroxisomes 
Interestingly, lipid and reactive oxygen species (ROS) metabolisms are tightly 
related to each other, thus the  peroxisome could be involved in the role of 
“metabolic signaling” (Karnati and Baumgart-Vogt, 2008) to regulate osteoblast 
(OB) differentiation and functions. According to the latest literature, more and 
more peroxisomal functions in the production and degradation of ROS and 
reactive nitrogen species (RNS) have been found (Fransen et al., 2012). Further, 
it has been realized that peroxisomes play a critical role in cell metabolism in 
addition to mitochondria. The peroxisomal enzymes involved in the production 
and scavenging of ROS (pro-and antioxidative enzymes) shown in the table 
below (Table.2.).  
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Table.2． Enzymes which generate ROS and antioxidative enzymes in mammalian peroxisomes (Antonenkov et al., 2010; 
Fransen et al., 2012). The Mn-superoxide dismutase (SOD2) used to be recognized as the peroxisome antioxidant enzyme, 
until it has been found that it is actually located solely within the mitochondrial matrix (Karnati et al., 2013).  
Enzymes in mammalian peroxisomes that generate ROS Antioxidative enzymes in mammalian peroxisomes 
Enzyme Substrate ROS Enzyme Substrate 
Palmitoyl-CoA oxidase Long- and very long-chain fatty acids, 
dicarboxylic fatty acids, glutaryl-CoA 
H2O2 Catalase H2O2 
Pristanoyl-CoA oxidase 2-Methyl-branched fatty acids H2O2 Peroxiredoxin I H2O2 
Trihydroxycoprostanoyl-
CoA 
Bile acids intermediates H2O2 Peroxiredoxin V (PMP20) H2O2 
Urate oxidase Uric acid H2O2 Cu/Zn-superoxide dismutase (SOD1) O2·- 
L-α-hydroxyacid oxidases Glycolate, lactate, medium- and long chain 2-
hydroxyacids 
H2O2 Epoxide hydrolase Epoxides 
Polyamine oxidase N-acetyl spermine/spermidine H2O2 Soluble glutathione S-transferase 
(member of kappa family) 
Hydroperoxides 
Pipecolic acid oxidase L-Pipecolic acid H2O2 Membrane bound (‘microsomal’) 
glutathione S-transferase 
Lipid 
hydroperoxides 
Sarcosine oxidase Sarcosine, L-proline H2O2   
D-amino acid oxidase D-isomers of neutral and basic amino acids H2O2   
D-aspartate oxidase D-isomers of acidic amino acids H2O2   
Xanthine oxidase Hypoxanthine, xanthine O2·-   
NO synthase, inducible L-arginine ·NO   
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Actually, ROS are mostly generated by mammalian peroxisomes which contain 
various enzymes called FAD (or FMN)-dependent oxidases. ROS are byproducts 
from functional catalytic activities of these enzymes, such as the H2O2 that is 
generated during the conversion of their substrates. As shown in Table.2. H2O2 is 
the most popular type of ROS present in mammalian peroxisomes. Further types 
of ROS such as the superoxide radicals and NO produced by xanthine oxidase 
or the inducible form of nitric oxide synthase have also been found in functioning 
peroxisomes (Angermüller et al., 1986; Loughran et al., 2005). 
In addition to the formation of ROS due to peroxisomal catalytic functional 
activities that could potentially damage the cell and initiate an alteration of cell 
signaling, peroxisomes can also function as an antioxidant defence system to 
maintain the oxidative homeostasis within and outside of the organelle due to 
their enzyme content of a variety of antioxidant enzymes. Especially Catalase is 
the most potent and fast enzyme degrading H2O2. Functional peroxisomes 
retains abundant amounts of various, I and V, SOD1, Epoxide hydrolase and 
glutathione S-transferase Peroxiredoxin (Table.2.) to decompose of ROS. 
Catalase and peroxiredoxins are targeted to the peroxisome via a modified PTS1 
signaling peptide and are present in the peroxisomal matrix of most mammalian 
cells. Moreover, Catalase is typical peroxisomal matrix enzyme that metabolizes 
H2O2  in a parallel with variety of substrates, such as ethanol, methanol, phenol 
and nitrites by its peroxidative activity (Oshino et al., 1973). 
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1.1.3.5. Summary on the enzyme composition and metabolical functions of 
the peroxisome 
Peroxisomal metabolic functions and the peroxisomal enzymes involved in these 
functions are summarized in blue schematic diagram in Figure.8. 
 
 
Figure.8. This scheme depicts the general functions of peroxisomes, including 
H2O2 metabolism, β-oxidation of distinct lipid derivatives as well as the synthesis 
of cholesterol and etherlipids. The picture was designed and provided with 
courtesy by Prof. Dr. Baumgart-Vogt. 
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1.2. Peroxisome biogenesis disorders 
1.2.1. The peroxisome biogenesis disorders and human diseases 
Peroxisome biogenesis disorders (PBDs) are defined as human diseases caused 
by the absence or deﬁciency in peroxisome biogenesis. PBDs are autosomal 
recessive diseases that arise from mutations in PEX genes that encode peroxins, 
required for the normal biogenesis of peroxisomes (Distel et al., 1996; Gould and 
Valle, 2000). Mutations in peroxins directly disrupt the apparatus required for the 
import of matrix proteins into the peroxisome containing a PTS1 or PTS2 
peroxisomal targeting signal. Zellweger syndrome (ZS), neonatal 
adrenoleukodystrophy (NALD), and infantile Refsum’s disease (IRD) represent a 
clinical continuum of autosomal recessive disease, called the disease of the 
Zellweger spectrum, with ZS being the most severe and IRD being the mildest 
form of the phenotypic spectrum (Maxwell et al., 2003). ZS is a multiple 
congenital anomaly syndrome and the patients show craniofacial abnormalities, 
including a high forehead, hypoplastic supraorbital ridges, epicanthal folds, 
midface hypoplasia, and a large anterior fontanel, accompanied by eye 
abnormalities, neuronal migration defects, hepatomegaly, and chondrodysplasia 
punctate(Steinberg et al., 2006; Wilson et al., 1986). Children with ZS exhibit 
typical skeletal deformations (Figure.9.), defects in the central nervous system, 
kidney cysts, liver cirrhosis, and adrenal insufficiency. Up to now, no curative 
treatment and therapy methodology are available for ZS patients and most of 
them survive less than a year(Gould and Valle, 2000).  
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Figure.9. Children with ZS exhibit skull deformities, a low nose saddle, 
hypertelorism, migrognathia and low ears. (Courtesy of Prof. R.J.A. Wanders, 
Amsterdam, Netherlands). 
Another type of a peroxiosomal biogenesis disorder with disruption of 
peroxisomal function protein is the PEX7 deficiency which causes rhizomelic 
chondrodysplasia punctata (RCDP) type 1 (Heymans et al., 1985; Purdue et al., 
1999). The RCDP shows a severe bone phenotype, the patients suffer from 
shortened long bones (humerus and femur) and shortened proximal 
limbs(Agamanolis and Novak, 1995; Braverman et al., 1997; Motley et al., 1997; 
Purdue et al., 1997; Shimozawa, 2007). 
1.2.2. Animal models for peroxisome biogenesis disorders  
Animal models for ZS have been developed through targeted disruption of the 
Pex2 (Faust and Hatten, 1997) Pex5 (Baes et al., 1997), Pex11β (Li et al., 2002b) 
and the Pex13 (Maxwell et al., 2003) genes. All four knockout animals exhibit 
many of the organ abnormalities typical of ZS, including hypotonia and impaired 
neocortex and cerebellar neuronal migration and maturation and die at or shortly 
after birth. In this dissertation, two of the animal models were used and will be 
described in the following. Newborn pups with the typical ZS phenotype of mouse 
lines are shown in Figure.10. and 11. 
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The function of PEX13 in docking complex for matrix protein import has been 
described in chapter 1.1.2.3. 
 
Figure.10. Appearance of new born pups with Pex13 KO exhibiting a typical 
Zellweger phenotype (Picture was taken in our laboratory, prior to the picture the new 
born pups were scanned with flat-panel volumetric computed tomography). 
The mouse mutant model with general Pex13 disruption was generated by exon2 
deletion in embryonic stem cell (ES) cells via the Cre/LoxP system. Pex13 mice 
exhibit many of the features of ZS patients, including intrauterine growth 
retardation, hypotonia, abnormal peroxisomal metabolism, and neonatal lethality. 
This phenotype is associated with defective peroxisome biogenesis and matrix 
import (Maxwell et al., 2003). 
Compared to the Pex13 knockout animal model, another ZS mouse model is the 
Pex11β knockout mouse which showed despite hardly altered biochemical 
peroxisomal matrix, the typical ZS phenotype, including hypotonia, a 
developmental delay, growth defects and a neuronal migration defect 
(Figure.11.). 
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Figure.11. Appearance of new born pups of Pex11β KO Mice, exhibiting stronger 
growth retardation phenotype than Pex13 KO mice with Zellweger syndrome. One 
litter of newborn mice with Pex11β gene heterozygous (+/-) and homozygous (-/-) 
offspring are depicted, the pups were anesthetized to take the picture.(Li et al., 2002b). 
In Pex11β KO mice, peroxisomes proliferation is detective, but organelles are 
present and functional as matrix proteins are imported normally. Despite this fact, 
the animals exhibit the typical morphological alterations of Zellweger syndrome 
(Li et al., 2002b). Interestingly, the peroxisomes in the animal models only show 
mild defects in their peroxisomal metabolical functions (Li et al., 2002b), even 
though in the literature before the assumption was made that the ZS 
pathogenesis in other animal models was caused by pathological defects in the 
VLCFA accumulation or plasmalogen deficiency. 
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1.3. Cells of the bone and their role in bone remodeling and the 
pathogenesis of osteoporosis 
1.3.1. The major types of bone cells and functions 
The bone cells, the organic matrix and mineral phase are three major 
components of the bone. Mineralized mature bone is made up by hydroxyapatite 
which is the crystallized state of calcium phosphate precipitation. This 
mineralized structure provides in the compressive strength and rigidity of mature 
bones. Three major types of cells, osteoclasts, osteoblasts and osteocytes with 
distinct functional features, are the key components of mammalian bone (see 
Figure 12). These cells play important role in the formation of the skeletal 
elements during embryogenesis and regulate homeostasis of dynamic bone 
remodeling in adult bones. Further a mineral phase and a significant amount of 
extracellular matrix are necessary for the osteogenesis. The ossification and 
bone remodeling are developmental precisely cooperated interplay process 
involved by different transcription factors and signaling proteins. Thus, 
dysfunctions or dysregulation of it can result in a number of human diseases, 
such as cleidocranial dysplasia and osteoporosis (Lian et al., 2004). 
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Figure.12. Schematic representation of the functional structures and locations of 
the three main types of bone cells: osteoblasts, osteocytes and osteoclasts, and the 
role of these 3 basic cell types in the bone remodeling process (Ewa, 2011). 
The osteoblasts derive from mesenchymal stem cells (MSC) differentiation and 
synthesize the bone matrix (see section 1.3.2.1). 
The osteocytes are normally recognized as the mature or post matured forms of 
osteoblasts that become trapped within calcified bone. The osteocytes play 
critical role in the osteogenic response to the stimuli of mechanical stress on 
bone. The bone remodelling process can be initiated by osteocytes with 
production of chemical messenger cascades once the physical strains have been 
sensed by it (Lanyon, 1992). 
The osteoclasts are differentiated from precursors of the monocyte macrophage 
lineage. To date their morphological identity is characterized by an efficient 
multinucleate cell, featured with uncertain lifespan and ultimate fate. The 
osteoclast degrades bone by attaching to a bone matrix surface and by secreting 
chloric acids and enzymes which can absorb the anorganic and organic 
components of bone matrix. Osteoclast absorb to the surface in a manner of 
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mobilizing themselves from one eroding pit of mineralized surface to another site 
(Suda et al., 1992). 
1.3.2. Osteobiogenesis, osteoblast differentiation and functional alterations  
1.3.2.1. The differentiation process of osteoblast and osteoblast maturation 
stage markers 
As mentioned above, the mature and functioning osteoblast originally are 
differentiated from MSC. However the whole differentiation process consists of 
several stages. Each stage can be identified by detecting of the expression levels 
of marker proteins. Early stage markers include the collagen, type I, alpha 1 and 
2 (Col1a1 and Col1a2) and master regulator runt-related transcription factor 2 
(Runx2) which decreases in expression in mature osteoblast. Further mature 
stage makers among others are osterix (Osx) and Bone γ-carboxyglutamic acid-
containing protein (Bglap=osteocalcin) (Table. 3.). These marker proteins can be 
used as an indicator for the OB differentiation process. For instance, the 
expression of many middle-mature stage markers, particularly osteopontin (Opn) 
and integrin-binding sialoprotein (Ibsp), are abundant in the pre-osteoblast 
indicating the pre-mature differentiation of pre-osteoblasts occurred. 
Table.3. The summary of the osteoblast differentiation stages and expression of 
marker proteins with schematic representation. 
 
 
Stage Osteoblast 
Progenitor 
Early stage  
Pre-osteoblast 
Pre-osteoblast Mature 
osteoblast 
Osteocyte 
Markers Col1a1 
Col1a2 
Runx2 
Runx2 
ALP 
Runx2 
OPN 
IBSP 
IBSP 
OPN 
OSX 
BGLAP 
OSX 
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1.3.2.2. Oxidative stress, age-related osteoblast differentiation delay and 
bone loss 
It has been known that loss of bone mass with advancing age in mice is caused 
by a decline in the abundance of osteoblasts and is associated with increased 
oxidative stress and decreased canonical Wnt signaling. The secreted proteins 
bind either to the Frizzled receptor, or the low density lipoprotein receptor-related 
protein 5 (LRP5) and LRP6 co-receptors, resulting in an increasing level of β-
catenin by preventing its degradation by the proteasome (Bodine, 2008; Glass 
and Karsenty, 2006a, b; Rodda and McMahon, 2006). It also has been found that 
age-related increased lipid oxidation product 4-hydroxynonenal (4-HNE) as well 
as an increased expression peroxisome proliferator-activated receptor-γ (PPARγ) 
were associated with bone loss in the skeleton (Almeida et al., 2009). 
The model of the suppression of β-catenin via an oxidized lipid-activated 
ROS/FoxO/PPARγ/β-catenin cascade was established to demonstrate the afore 
mentioned mechanism (see section 1.3.1 and Figure.13.). There are two 
consequences of the oxidation of Polyunsaturated fatty acid (PUFA) generated 
by ROS and lipoxygenases which increase the oxidative burden of the skeleton 
via the generation of 4-HNE. Firstly, oxidative stress activates the forkhead box 
O (FoxO) family of transcription factors, which in turn attenuate β-catenin/T-cell 
factor (TCF)-mediated transcription because of competition between FoxO and 
TCF for a limited pool of β-catenin, leading to derepression of PPARγ 
transcriptional capability. Secondly, oxidized PUFAs activate PPARγ with the 
oxidation products as ligand and active the PPARγ transcriptional activity. For 
both of the consequences, the activation of PPARγ will result in decrease of 
osteoblastogenesis and increase of adipogenesis (Almeida et al., 2009).  
Via this cascade, lipid oxidation contributes to the decline in osteoblast number 
and bone formation that occurs with aging by attenuating the canonical Wnt 
signaling required for the differentiation and survival of osteoblasts (Almeida et 
al., 2009).  
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Figure.13. Suppression of β-catenin by an oxidized lipid-activated 
ROS/FoxO/PPARγ/β-catenin cascade, leading to a decreased bone formation. 
Graph modified from (Almeida et al., 2009). 
Regarding the facts, oxidative stress compromises the functions of canonical Wnt 
signaling in the regulation of OB differentiation from MSC with the negative role 
of PPARγ in this circumstance. The activation of this cascade contributes to the 
osteoblast differentiation defect and the loss of bone with age. Because the 
activation of PPARγ regulates the proliferation and the quantity of peroxisomes in 
a positive manner, we hypothesize that peroxisomes at least partially play a role 
in maintaining the homeostasis between oxidative stress, lipid ligands and 
osteoblastogenesis.  
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1.3.2.3. Regulation of the bone absorption by osteoblast via the 
RANKL/OBG system 
 
 
Figure.14. The role of osteoblasts in the mechanism of pre-osteoclast 
differentiation via osteoprotegerin (OPG) on the receptor activator of nuclear 
factor κ-B ligand (RANKL) mechanism. OPG can trap and neutralize of RANKL which 
activate osteoclasts by its receptor RANK(Ewa, 2011). 
In addition to osteoblasts that promote the formation of bone, another key player 
in adult bone homeostasis is the osteoclasts (Harada and Rodan, 2003). The 
multinucleate cells derive from precursors of the monocyte–macrophage lineage 
(Boyle et al., 2003). These osteoclast cells can degrade bone tissue efficiently by 
removing its mineralized matrix and breaking up the organic bone structure 
(Boyle et al., 2003). Therefore, the amount of adult bone tissue is highly 
dynamically maintained by the remodeling process, which is in turn controlled by 
the interplay of osteoclasts and osteoblasts. This remodeling provides the adult 
bone with a mechanism for self-repair and adaptation to stress. Consequently, 
the differentiation and proliferation of osteoblast and osteoclast progenitor cells 
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significantly influences the reabsorption and formation of bone. Although the 
mechanisms of osteoblast and osteoclast differentiation are different with distinct 
progenitors, the differentiation and functions of them are strongly regulated by 
cytokine interactions with these two types of bone cells(Khosla, 2001). Two 
cytokines are expressed and released from osteoblasts. The macrophage 
colony-stimulating factor (M-CSF) and receptor activator of NF-B ligand 
(RANKL) are essential for the genesis of osteoclasts (Figure.14.). The RANKL 
binds the membrane-anchored receptor activator of the nuclear factor B (RANK), 
on the surfaces of both osteoclast progenitors and mature osteoclasts, inducing 
the activation of the nuclear factor of activated T cells cytoplasmic 1 (NFATc1) 
and promoting the osteoclastogenesis (Khosla, 2001; Nakashima and 
Takayanagi, 2011). The RANKL/RANK cascade can be blocked by 
osteoprotegerin (OPG), a cytokine and a soluble decoy receptor of RANKL 
produced by osteoblasts that prevents RANKL from binding to RANK, thus 
limiting osteoclast formation(Khosla, 2001). Therefore, the extent of proliferation 
and differentiation of osteoclast progenitors in bone and even the bone mass are 
determined by the relative concentrations of RANKL and OPG (Boyce et al., 
2012). 
1.4. Bone phenotype and peroxisomal phenotype in the Sirt1 KO mouse 
model 
Sirtuins are highly conserved NAD+-dependent protein deacetylases and/or ADP-
ribosyltransferases that can extend the lifespan of several animal models. The 
mammalian Sir2 ortholog, SIRT1, is known to be a global deacetylase that 
deacetylates many transcriptional factors and cofactors, playing an important role 
in aging and disease (Guarente, 2011; Imai et al., 2000; Li and Kazgan, 2011). 
Recent studies have shown that SIRT1 is a key regulator of bone development 
and remodeling. For instance, SIRT1 transgenic mice are protected from age-
induced bone loss (Herranz et al., 2010). Conversely, SIRT1 heterozygous 
female mice display a reduction in bone mass due to decreased bone formation 
and increased marrow adipogenesis (Cohen-Kfir et al., 2011). Moreover, specific 
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deletion of SIRT1 in mesenchymal stem cells leads to decreased MSC 
differentiation to osteoblasts and chondrocytes, as well as a reduction in cortical 
bone thickness and trabecular volume in mice (Simic et al., 2013). A few 
pathways have been proposed to explain the observed role of SIRT1 in bone 
development and remodeling, such as deacetylation and activation of -catenin, 
a Wnt signaling molecule involved in the self-renewal and differentiation of 
mesenchymal stem cells (Ling et al., 2009). However, SIRT1 could potentially 
affect bone homeostasis partially through other signaling pathways, particularly 
the PPARs. PPARs, including PPAR, /, and , belong to the nuclear receptor 
superfamily. The PPARs form heterodimers with the retinoid X receptor (RXR), 
on function as lipid sensors through the direct binding of a variety of natural lipids 
and synthetic agonists, such as peroxisome proliferators, to the ligand-binding 
domain. Upon lipid binding, each of these receptors activates the transcription of 
a family of genes involved in lipid homeostasis, including many peroxisomal 
enzymes and proliferating proteins, thereby modulating systemic energy 
metabolism in response to nutrient availability (Shulman and Mangelsdorf, 2005).  
In this dissertation, using primary osteoblast and osteoblast cell line, as well as 
SIRT1 knockout mouse model, I could show that SIRT1 regulates osteoblast 
differentiation and functions in part through the modulation of peroxisomal 
function. Loss of SIRT1 leads to pre-mature differentiation of pre-osteoblasts and 
impairs peroxisome biogenesis and function and further results in abnormal bone 
development in mice.  
In addition to the peroxisome proliferator-activated receptor γ-coactivator 1α (Pgc 
-1α), Sirt1 has been found to regulate the activity and/or transcription of protein 
kinase B, mammalian target of rapamycin (mTOR) , FoxO 1 and 3a and 
myogenic determination factor, all of which are central players in the regulation of 
the energy status in skeletal muscle via actions on catabolic and anabolic 
signaling (Ryall, 2012).  
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2. Aims of the study 
The strong calcification of cartilage in the patella and the growth plate, as well as 
ossification defect inducing and bone deformation in ZS patients, suggest that 
the peroxisome may play a very important role in ossification and bone 
development(Qian, 2010a): Previous research in our laboratory has revealed that 
the numerical abundance and the enzyme composition in all distinct cell types of 
the skeleton are significantly different and are increased as long as OB are 
approaching to maturation (Qian, 2010a). Moreover, peroxisome are very 
abundant in proliferating and even more abundant in hypertrophic cartilage of 
growth plates(Qian, 2010a). Therefore, we hypothesized that the peroxisomes 
play an important role in maintaining the homeostasis of bone cell ROS and lipid  
metabolism, the dysfunction of peroxisomes should be induced by peroxisome 
biogenesis deficiency, moreover should result in accumulation of lipids and ROS 
leading in consequences to lipid toxicity and increased oxidative stress. By these 
mechanisms, bone mineralization could be delayed by OB differentiation and 
maturation defect. To test these above hypotheses, the aims of my research 
were: 
1. To investigate whether peroxisome deficiency would interfere with OB 
differentiation and maturation and how the normal functions of OB is 
disturbed by the peroxisome defect in using primary OB cells isolated from 
the calvaria of Pex11β and Pex13 KO mice model. 
2. To investigate the different mechanisms resulting in the osteoblast 
differentiation delay or osteoblast dysfunction induced by Pex11β and 
Pex13 deficiency. 
3. Since the SIRT1 control lipid metabolism via PGC1α and regulates PPAR 
functions and thus peroxisome genes are regulated by these nuclear 
receptors (Li, 2013), therefore, Sirt1 KO/WT animals and Sirt1 KO/WT OB 
were used to characterize the alteration induced in stem cell recruitment, 
ossification, and mice OB differentiation. A major focus has been laid in 
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characterizing the peroxisomal compartment and related gene expression 
in the Sirt1 KO animal model. 
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3. Materials and Methods 
3.1. General Materials used in the laboratory  
3.1.1. Chemicals for the general application of molecular and 
morphological experiments 
The chemicals used in this thesis with corresponding suppliers are listed in 
Table.4.: 
Table.4. The chemicals used in experiments 
Chemicals  Company name 
Acrylamide Roth, Karlsruhe, Germany 
Agarose LE Roche, Grenzach-Wyhlen, 
Germany 
Alizarin Red S Fluka, Neu-Ulm, Germany 
Ascorbic acid Sigma, Steinheim, Germany 
Bradford reagent Sigma, Steinheim, Germany 
Bromophenol blue Riedel-de-Haën, Seelze, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Ciprofibrate Sigma, Steinheim, Germany 
Citric acid Merck, Darmstadt, Germany 
Di-Potassium hydrogen phosphate  Merck, Darmstadt, Germany 
Ethanol Riedel-de-Haën, Seelze, Germany 
Ethidium bromide Fluka, Neu-Ulm, Germany 
Ethylene diamine tetraacetic acid 
(EDTA) 
Fluka, Neu-Ulm, Germany 
Ethylene glycol-bis (2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA) 
Fluka, Neu-Ulm, Germany 
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Glycine Roth, Karlsruhe, Germany 
Glycerol Sigma, Steinheim, Germany 
β-glycerolphosphate Sigma, Steinheim, Germany 
Hydrogen peroxide  Merck, Darmstadt, Germany 
4-(2-Hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Roth, Karlsruhe, Germany 
Ketamin Bayer, Leverkusen, Germany 
L-Glutamate  Cambrex BioScience, MD, USA 
Mowiol 4-88 Polysciences, Eppelheim, Germany 
3-[N-Morpholino]-propanesulfonic acid 
(MOPS) 
Serva, Heidelberg, Germany 
N-ACETYL-L-CYSTEINE Sigma, Steinheim, Germany 
N-Propyl-gallate Sigma, Steinheim, Germany 
Paraformaldehyde (PFA) Sigma, Steinheim, Germany 
Penicillin/Streptomycin  PAN Biotech, Aidenbach, Germany 
Phenylmethanesulfonyl fluoride (PMSF) Serva, Heidelberg, Germany 
Ponceau S Serva, Heidelberg, Germany 
Potassium dihydrogen phosphate  Merck, Darmstadt, Germany 
Potassium hydroxide  Fluka, Neu-Ulm, Germany 
Rotiphorese Gel 30 Roth, Karlsruhe, Germany 
RNaseZap Sigma, Steinheim, Germany 
Sodium carbonate Merck, Darmstadt, Germany 
Sodium chloride Roth, Karlsruhe, Germany 
Sodium hydrogen carbonate Merck, Darmstadt, Germany 
Sodium hydroxide Merck, Darmstadt, Germany 
Sucrose Merck, Darmstadt, Germany 
Sodium dodecyl sulphate (SDS) Sigma, Steinheim, Germany 
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Tetramethylethylenediamine (TEMED) Roth, Karlsruhe, Germany 
Trishydroxymethylaminomethane (Tris) Merck, Darmstadt, Germany 
Triton X-100 Sigma, Steinheim, Germany 
Trypan blue Sigma, Steinheim, Germany 
Tween 20 Fluka, Steinheim, Germany 
Uranyl acetate Merck, Darmstadt, Germany 
Xylene Merck, Darmstadt, Germany 
3.1.2. Laboratory general instruments  
All instruments used for the experimental parts of this thesis are summarized with 
appropriate supplier in Table.5. and listed in alphabetical order: 
Table.5. Laboratory general instruments used in experiments listed by 
alphabetical order. 
Type of Instruments Manufacturer  
AGFA Horizon Ultra Colour Scanner  AGFA, Mortsel, Belgium 
Biocell A10 water system Milli Q-Millipore, Schwalbach, Germany 
Biofuge Fresco Heraeus, Hanau, Germany 
Biofuge Pico Heraeus, Hanau, Germany 
Bio-Rad electrophoresis apparatus 
(Sub Cell GT) system 
Bio-Rad, Heidelberg, Germany 
Dish washing machine (G 78 83 CD) Miele, Gütersloh, Germany 
Cary 50 Bio-UV-visible 
spectrophotometer 
Varian, Darmstadt, Germany 
Gel-Doc 2000 gel documentation 
system 
Bio-Rad, Heidelberg, Germany 
Flat–panel volumetric computed 
tomography (Obert et al., 2005) 
GE medical systems, Milwaukee, WI 
Fraction collector Heidolph pump 
drive 5101 
Heidolph Instruments, Schwabach, 
Germany 
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Hera cell 240 incubator Heraeus, Hanau, Germany 
Hera safe, clean bench KS-12 Heraeus, Hanau, Germany 
Ice machine, Scotsman AF-100 Scotsman Ice Systems, Vernon Hills, IL, 
USA 
I Cycler PCR machine  
MiQ2 optical module  
Bio-Rad, Heidelberg, Germany 
Leica DMRD fluorescence 
microscope 
Leica, Bensheim, Germany 
Leica DC 480 camera   Leica, Bensheim, Germany 
Leica TP1020 embedding machine Leica, Nussloch, Germany  
Leica TCS SP2 confocal laser 
scanning microscope 
Leica, Nussloch, Germany 
Leica SM 2000R rotation microtome Leica, Nussloch, Germany  
Microwave oven MB-392445 LG, Willich, Germany 
Mini-Protean 3 cell gel chamber Bio-Rad, Heidelberg, Germany 
Microtome stretching water bath 
Type 1003 
Vieth Enno, Wiesmoor, Germany 
Multifuge 3 SR centrifuge Heraeus, Hanau, Germany 
Oven HERAEUS T 5050 EKP Heraeus, Hanau, Germany  
pH meter E163649 IKA, Weilheim, Germany 
Pipettes Eppendorf, Hamburg, Germany 
Potter-Elvehjem homogenizer 
8533024 
B.Braun, Melsungen, Germany 
Power supply - 200, 300 and 3000 Xi Bio-Rad, Heidelberg, Germany 
Pressure/Vacuum Autoclave FVA/3 Fedegari, Albuzzano, Italy 
Pump Drive PD 5001 Heidolph Instruments, Schwabach, 
Germany 
Sorvall Evolution RC centrifuge Kendro, NC, USA  
SmartspecTM 3000 
spectrophotometer 
Bio-Rad, Heidelberg, Germany 
T25 basic homogenizer IKA, Staufen, Germany 
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Thermo plate HBT 130 Medax, Kiel, Germany 
Thermo mixer HBT 130 HLC, BioTech, Bovenden, Germany 
Trans-Blot SD semi dry transfer cell Bio-Rad, Heidelberg, Germany 
TRIO-thermoblock  Biometra, Göttingen, Germany 
Ultra balance LA120 S Sartorius, Göttingen, Germany 
Ultra Turrax T25 basic homogenizer Junke & Kunkel, Staufen, Germany 
Vortex M10 VWR International, Darmstadt, Germany 
Water bath shaker GFL 1083  GFL, Burgwedel, Germany 
3.1.3. The General materials for cell culture 
The General materials and the all the cell culture medium used for cultivation of 
primary osteoblast and MC3T3-E1 cells are listed alphabetically in Table.6.: 
Table.6. General materials for cell culture listed with notice of corresponding 
suppliers 
General materials and culture medium Company name 
Cover slips Menzel-Gläser, Braunschweig, 
Germany 
Culture dish (35mm) BD Biosciences, Heidelberg, Germany 
Culture dish (60mm) BD Biosciences, Heidelberg, Germany 
Fetal bovine serum Thermo Fisher Scientific, Schwerte, 
Germany 
Filter tips and canules Braun, Melsungen, Germany 
Microtome blade A35 Feather, Köln, Germany 
Minimum essential Medium (MEM) α 
medium 
Invitrogen, Karlsruhe,Germany 
Molecular weight markers (DNA, RNA) Fermentas, St.Leon-Rot, Germany 
N-Acetyl-L-cysteine Sigma, Steinheim, Germany 
Multi-well cell culture plates (12 wells) BD Biosciences, Heidelberg, Germany 
Nylon meshes (100, 20 and 10µm) Bückmann, Mönchengladbach, 
Germany 
Penicillin-Streptomycin Life technology, Darmstadt, Germany 
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3.2. Experimental animals  
3.2.1. Pex11β KO and Pex13 KO animals in Germany  
All experimental animals of the Pex11β and Pex13 mouse line were maintained 
under specific pathogen free (SPF) conditions in the Central Animal Facility of 
the Justus Liebig University. The Pex11β KO and Pex13 KO mice with C57BL/6J 
background were generated by crossbreeding of the heterozygous adult mice (Li 
et al., 2002b; Maxwell et al., 2003). The genotyping of these animals was 
performed by using genomic DNA isolated from tissue sampled mouse tails. The 
pregnancy of heterozygous female mice was calculated according to the 
identification of a visible vaginal plug (=E0.5). All experimental mice were 
delivered to the animal operation room in our laboratory at days E19 of the 
fetuses. 
All animal experiments in my laboratory works were approved by the German 
Government Commission of Animal Care (Permission number: 471M1016 
Peroxisomen G120/23). 
3.2.2. Sirt1 whole body KO mice experiment in the USA  
General Sirt1 knockout mice (Sirt1 KO) and myeloid-specific Sirt1 knockout mice 
(Sirt1 Mac-KO) in C57BL/6 background were generated as described (McBurney 
et al., 2003; Purushotham et al., 2012; Schug et al., 2010). All animal 
experiments were conducted in accordance with guidelines of US NIEHS/NIH 
Animal Care and Use Committee. 
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3.3. Methods 
3.3.1. Primary osteoblasts and MC3T3-E1 pre-osteoblast-like fibroblast cell 
line 
3.3.1.1. Primary osteoblast cell isolation and culture 
The pre-osteoblasts were isolated from calvariae of 19 day old embryos (E19) 
Pex11β, Pex13 and Sirt1 KO and WT mouse pups. After the fibrous tissue 
surrounding (periost) the bone was scraped off from the isolated calvariae, the 
whole bone was trimmed and cut into small pieces and transferred into 15 ml 
Falcon tubes, tissue was demineralized with 4 mM EDTA with shaking water at 
37° C for 10 min, and washed thereafter with 1×Phosphate buffered saline pH 
7.4 (PBS) solution (Millipore Darmstadt, Germany) for 5 min. The 
demineralization was repeated once more under the same condition. The 
demineralized bone pieces were further digested with collagenase 2 (PAA, Cölbe, 
Germany) at 37° C for 15 min. Five consecutive digestions were carried out. The 
first two digestions mainly contained fibroblasts which were discarded. The last 3 
digestions were sieved through a polypropylene mesh with 200–297 μm2 pore 
size into a 50 ml Falcon tube. Isolated pre-osteoblast were harvested with 5 min 
100 xg centrifugation and cultured in α-MEM complemented with 2 mM Glutamin 
(Table.6.) containing 10% fetal bovine serum (Table.6.), 100 U/ml penicillin G 
and 100 µg/ml streptomycin at 37° C in a humidified atmosphere of 95% air and 
5% CO2. The following day, the medium was changed to remove any non-
adherent cells. Thereafter, the medium was changed every two days. The purity 
of osteoblast isolated from mouse pups calvariae with this method was more 
than 95%(Qian, 2010a). 
3.3.1.2. Cell culture of MC3T3-E1 pre-osteoblast-like fibroblast cell line  
The MC3T3 cell line was established by Sudo originally and colleagues by 
isolation calvaria of C57BL/6 fetuses and was described to differentiate into 
mature osteoblast (Sudo et al., 1983). The non-transformed MC3T3-E1 cells 
were purchased from the Deutsche Sammlung von Mikroorganismen und 
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Zellkulturen (DSMZ, Braunschweig, Germany), kindly provided by Prof. Dr. Katrin 
Susanne Lips at University of Giessen Germany (En-Nosse et al., 2009). Cell 
cultures were maintained in the standard osteoblast medium α-MEM (Table.6.) 
supplemented with 10% fetal bovine serum (Table.6.), 100 U/ml penicillin G and 
100 µg/ml streptomycin (Table.6.) at 37°C in a humidified atmosphere of 95% air 
and 5% CO2.  
3.3.1.3 Induction of pre-osteoblast maturation and osteoblast cell culture 
mineralization evaluation via Alizarin Red-S staining  
After primary osteoblast isolation from Pex13 KO and WT pup calvariae, the cells 
were cultured in osteoblast standard medium for 10 days. The cells were seeded 
in separate cell culture dishes at a density of 104 cells/cm2 and the medium was 
changed to induce the differentiation of osteoblast. The α-MEM was 
supplemented with 10% fetal bovine serum (Table.6.), 100 U/ml penicillin G, 100 
µg/ml streptomycin (Table.6.), 50 µg/ml ascorbic acid (Sigma, St. Louis, USA) 
and 10 mM β-glycerophosphate (Sigma, St. Louis, USA). The mineralization was 
evaluated with an Alizarin Red-S staining analysis which was carried out in an 
interval of 3 days up to 24 days calculated from the day of the cell isolation. 
Prior to fixation of cells, the medium was removed and the cells were washed 
twice with PBS solution to completely remove red residues of medium. The 
washed cells were fixed with 95% ethanol for 15 min at room temperature (RT). 
After fixation, the cells were washed 3 times with distilled water. Finally the fixed 
osteoblast were stained by incubation with 0.1% Alizarin Red-S in Tris-HCl (pH 
8.3) for 40 min at 37° C. During the incubation time, the progress of the staining 
was several times monitored by observing the samples with phase contrast 
microscope until the red staining of calcified extracellular matrix formation 
became visible and identifiable. To stop the staining process, the cells were 
washed 3 times for 5 min with distilled water. After the red residues were 
completely removed, the culture dishes containing stained cells were air-dried at 
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RT. After the culture dishes were completely dried, they were scanned with an 
ESPON perfection 1660 photo scanner.  
3.3.2. Transfection of MC3T3-E1 cells and primary osteoblast  
3.3.2.1. Transfection of MC3T3-E1 cells with Mus musculus Pex11β shRNA 
plasmids to knockdown the Pex11β gene expression. 
To knockdown the Pex11β gene expression in MC3T3-E1 cells, the 
SureSilencing shRNA Plasmids for plasmid-based RNAi were purchased from 
Qiagen (Cat.336311 KM26107G). MC3T3-cells were transfected with Trans IT® 
LT-1 transfection Reagent purchased from Mirus (MIR2300) according to the 
standard protocol from the manufacturer Mirus for this reagent. 24 hours prior to 
each transfection, 5x105 cells were seeded onto each well of 6-well plates. For 
each well, a mixture of lipofection solution was prepared by mixing 2 µl of Trans 
IT® LT-1 transfection reagent and 110 µl of DMEM serum free medium. After this 
lipofection solution was incubated at RT for 15 min, 1 µg of plasmid DNA was 
added and gently mixed. This final mixture was further incubated for 15 min at 
RT before transfection. Before transfection, for each well the old medium was 
replaced by filling with 2 ml of fresh standard osteoblast medium containing 10% 
FBS. The 100 µl of the final incubated lipofection solution with plasmid mixture 
complex was added drop wise. Meantime, the dispersal of the complex can be 
reached by swirling the plates. After transfection, to ensure the transfection 
efficiency, the transfected osteoblast cell cultures were incubated at 37 °C in the 
cell culture incubator for 48 hours prior to the application of the substances for 
either gene expression knockdown or Luciferase purposes. 
Four types of plasmids which had been made by inserting different functional 
shRNA sequences (Table.7.) in the same plasmid backbone and one negative 
control plasmid which had been made by inserting a scrambled sequence into 
the expression vector was provided by the manufacturer for various cell types 
and conditions the sequences of which are listed in Table.7. 
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Table.7. The Pex11β shRNA plasmid sequences 
Clone ID Insert Sequence  Catalog No: 336311 KM26107G 
1 CCACAACTGGCTTT
GAAGTTT 
Marker gene : Green Fluorescent 
Protein (GFP)  
2 GTACTTTGCCTGTG
CAAGT 
Description  Peroxisomal biogenesis 
factor 11β 
3 TGCTTATGAGATTCG
CCTATT 
Gene symbol 
Pex11β 
4 TCTGAGCCTCGGAC
GAAAGTT 
UniGene no: 
Mm.20901 
Negative  
Control 
GGAATCTCATTCGAT
GCATAC 
RefSeq 
Accession no.: 
MN-011069 
The screening of the Pex11β gene expression knockdown was performed by 
Semi-Quantitative polymerase chain reaction (RT-PCR) with the primer pair described 
in Table.8. For this purpose the isolated RNA from the transfected MC3T3 cells 
48 hours after the transfection was transcribed in cDNA (see section 3.4.1). For 
further quantification of the knockdown of the Pex11β gene expression, the 
cDNA was further checked with the Quantitative RT-polymerase chain reaction 
(qRT-PCR) for quantification of the knockdown with the primers described in 
Table.8.  
3.3.2.2. Transfection of MC3T3-E1 cells with Sirt1 shRNA Lentivirus to 
generate a stable knockdown of the Sirt1 gene 
Mouse SIRT1 shRNA Lentiviral Particles (SantCruz SC-153192-v) and control 
shRNA Lentiviral Particle (SantCruz sc-108080) were used to transfect MC3T3-
E1 cells according to the manufacturer’s standard protocol (Santa Cruz Texas 
USA). The cells were transfected with a ratio of 2 infectious units/cell in 
supplemented medium containing 10% fetal bovine serum, 100 U/ml penicillin G 
and 100 µg/ml streptomycin, 5 g/ml polybrene (Sigma, St. Louis, USA). The 
medium was replaced the following day to remove the polybrene and cultured for 
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further experiments. The transfected cells were selected with 5 μg/ml Puromycin 
dihydrochloride (A1113803 Invitrogen) for 6 days. Thereafter culturing in non-
selection medium for 2 days followed before the cells were processed for 
experiments. 
3.4. Molecular biological experiments  
3.4.1. RNA isolation from primary osteoblast and MC3T3-E1 cell culture and 
the reverse transcription to generate cDNA 
Total RNA was isolated from primary osteoblasts and MC3T3-E1 cells by using 
the RNeasy Mini Kit®, according to the manufacturer’s protocol (Qiagen, 
Heidelberg, Germany). The cells were collected and lysed directly from the cell 
culture dish by using cell Scrapers (Greiner bio-one541080) with 350 µl/well RLT 
buffer provided by the kit. The cell lysate was homogenized by directly 
transferring it to a QIAshredder spin column and centrifuging at a speed of 
12,000x g for 2 min at room temperature (RT). Each RNA preparation was 
subjected to DNase I digestion to remove possible contamination of genomic 
DNA by using RNase-free DNAse set (Qiagen Cat 79254) by which the 
contaminated genomic DNA can be directly digested within RNeasy/QIAamp® 
columns. The quantity and integrity of the isolated RNA was assessed with the 
NanoDrop™ 8000 Spectro-photometer and RNA 6000 Nano LabChips (Caliper 
Life Sciences GmbH, Mainz, Germany). The isolated total RNA from primary 
osteoblasts and MC3T3-1 cells was reversely transcribed to cDNA. First-strand 
cDNA was synthesized from 1.0 µg of DNAse I-treated total RNA with oligo (dT) 
12-18 primers using Superscript II reverse transcriptase (Invitrogen, Karlsruhe, 
Germany) according to the manufacturer’s protocol.  
3.4.2. Semi-quantitative polymerase chain reaction and agarose gel 
electrophoresis. 
The PCR reaction mix contained the 450 ng template cDNA, 10 mM dNTPs, 1 
unit Taq DNA polymerase and 10×PCR buffer (Eppendorf, Hamburg, Germany). 
PCR reaction was performed in the Bio-Rad iCycler C1000 (Bio-Rad 
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Laboratories, München, Germany) with the following parameters: denaturation at 
95°C for 2 min; followed by 32-45 cycles of denaturation at 95°C for 30 s, 
annealing at 50-65°C for 1 min, extension at 72°C for 1 min; and a final extension 
at 72°C for 7 min.  
The target gene expression results were determined by the analysis of the RT-
PCR product size via agarose gel electrophoresis. For this purpose, a 2% 
agarose gel, containing 0.5 μg/ml ethidium bromide electrophoresis in 1 x TAE 
buffer was casted. For each RT-PCR reaction, 10 μl of the product was stained 
with SYBR® Gold (Bio-Rad) and loaded on the gel and run at voltage of 90 V for 
60 min. After the electrophoresis, the gel was photographed with UV light using 
the Gel-Doc 2000 documentation system from Bio-Rad Laboratories (München, 
Germany). The size of the RT-PCR products was measured by comparing to the 
bands of a 100bp DNA Ladder GeneRuler (100 bp) or 1000 bp ladder 
(Fermentas). Gene expression was analyzed by comparing the intensity and 
thickness of the gene of interest to that of 28S rRNA (reference gene) which was 
run in parallel on the same agarose gel. All primers for RT-PCR experiments are 
listed in alphabetical order in Table.8. depicting also the annealing temperature 
used for the PCR and the size of amplified product. 
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Table.8. RT-PCR primer pairs 
Gene 
names 
Forward primer(5’-3’) Reverse primer(5’-3’) Tm(° C) 
Product 
(bp) 
Abcd1 GAGGGAGGTTGGGAGGCAGT GGTGGGAGCTGGGGATAAGG 65 465 
Abcd3 CTGGGCGTGAAATGACTAGATTGG AGCTGCACATTGTCCAAGTACTCC 64 523 
Catalase ATGGTCTGGGACTTCTGGAGTCTTC GTTTCCTCTCCTCCTCATTCAACAC 64 833 
FoxO1 GGGAGAATGTTCGCTTTCTGGT CCACCTCATCAGGCACTTCTC 56 662 
FoxO3 CACTGAGGAAAGGGGAAATGGG TGGGGTCCCACAGGCTCAAAAG 58 540 
FoxO4 TTGTGCCTAGAAGAGAGTGCTG ATTTGACACACTTCCCCACTCC 54 531 
Ho-1 GCACTATGTAAAGCGTCTCCACGAG CCAGGCAAGATTCTCCCTTACAGAG 65 610 
Nrf2 CCACTGGTTTAGCCATCTCTCC GTGGACATTAGCCCTTCCAAAC 64 364 
Pex11β GTATGCCTGTTCCCTTCTCG CTCGGTTGAGGTGACTGACA 65 216 
Sirt1 GGTAGAGCCTGCATAGATCTTCA TGGCAGTAATGGTCCTAACTGGG 62 512 
Sirt2 CCATGACCTCCCGCAGGACAGCG- GGGTCCCCAGGAAAGGGAGCCTA 69 505 
Sirt3 GTGCCCCGACTGCTCATCAATCG CCGATCAACATGCTAGATTGCCC 55 523 
Sirt4 CACCCGGTCTGACGATTTGGCTT CCGTGTTAGCTATTGCTCCTGCC 64 483 
Sirt5 TTGCTGCGACCTCACGTGGTGTG GGAAGGACTTGACAGCCTCTTCC 65 505 
Sirt6 GGGGACTGAGCCCAGGTTTGCAT CTTCTGGGAGCCTGGGGCCCTTA 67 494 
Sirt7 TATCCTAGGAGGCTGGTTTGGCA GGAGGCTTAGTTAGATTCTCCCT 59 503 
28srRNA CCTTCGATGTCGGCTCTTCCTAT GTGGACATTAGCCCTTCCAAAC 65 254 
Tm = Annealing temperature; bp = base pairs. 
All primers were designed to specially amplify the parts of cDNA sequences of 
the corresponding mRNA of interest. The primer design was achieved by 
published cDNA sequences using the Nucleotide Database of NCBI 
(http://www.ncbi.nlm.nih.gov/nucleotide/). The online software “Primer3” 
(http://frodo.wi.mit.edu) was used to analyse and select the most suitable primers 
which were standardized at a length of around 20-22 base pairs (bp). The “GC” 
content was kept around 40-60% out of total length of each primer and the 
annealing temperature (Tm) difference between forward and reverse primer of 
each primer pair was limited to less than 4° C to ensure the specific binding 
capacity. To prevent amplification of genomic DNA extron-spanning primers were 
designed. To ensure the specificity of each primer, BLAST searches against the 
EST and non-redundant mouse transcriptome databases (http://www.ncbi. 
nlm.nih.gov/blast/Blast.cgi) were applied to ensure no nucleotide matches at the 
3’ ends of each primer (Tanaka et al., 2012). All primers used in the experiments 
were synthetized by Eurofins MWG Operon Germany, and the PCR conditions 
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for each primer pair were optimized with a temperature gradient from 55-70°C on 
a BioRad iCycler prior to further experiments. 
3.4.3. Quantitative real time-polymerase chain reaction 
Quantitative real time-polymerase chain reaction (qRT-PCR) was performed 
using a SYBR Green PCR Master Mix (Applied Biosystems) with the IQ5® I 
cycler (Bio-Rad, Müchen, Germany) using the standard protocol provided by 
manufacturer (thermal cycling 94˚C for 3 min followed by 45 cycles at 94˚C for 30 
s, Tm =60 °C for 45 sec and 72°C for 1 min.). The mRNA levels were normalized 
to the osteoblast differentiation stable references gene Actb, Hmbs and Hprt1 
(Stephens et al., 2011); the sequences of the primers used for the qRT-PCR are 
noted in alphabetical orders in Table.9. 
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Table 9. Sequences of the primers used for the qRT-PCR 
Gene Name Sense 5’-3’ Antisense 5’-3’ 
Abcd1 ACAGTGCCATCCGCTACCTA ATGAGCTACTAGACGGCTTCG 
Abcd3 TCAGAATGGGACGCTCATTGA TGGCAGCGATGAAGTTGAATAA 
Actb CTCTGGCTCCTAGCACCATGAAGA  GTAAAACGCAGCTCAGTAACAGTCCG 
Acox1 CCGCCACCTTCAATCCAGAG CAAGTTCTCGATTTCTCGACGG 
Acox2 ACGGTCCTGAACGCATTTATG TTGGCCCCATTTAGCAATCTG 
Acox3 TTCTAGTGCTGATTAACTGCCTG AGAAACGAAAACTGTGGTTCCAA 
Alp AGGGCAATGAGGTCACATCC CACCCGAGTGGTAGTCACAAT 
Bglap ATGCTTCTCAGAGCCTCAGTC TAGGCGGTCTTCAAGCCATA 
Catalase TGGCACACTTTGACAGAGAGC CCTTTGCCTTGGAGTATCTGG 
Col1a1 GCTCCTCTTAGGGGCCACT ATTGGGGACCCTTAGGCCAT 
Col1a2 AGCTTTGTGGATACGCGGAC TAGGCACGAAGTTACTGCAAG 
Hmbs  GAGTCTAGATGGCTCAGATAGCATGC  CCTACAGACCAGTTAGCGCACATC 
Hprt1 GAGGAGTCCTGTTGATGTTGCCAG  GGCTGGCCTATAGGCTCATAGTGC 
Ibsp ACGGCGATAGTTCCGAAGAG CTAGCTGTTACACCCGAGAGT 
Mfp1 AATACAGCGATACCAGAAGCCA CCAGCTCTAGTCCTCCTCCA 
Mfp2  TTAGGAGGGGACTTCAAGGGA TCGCCTGCTTCAACTGAATCG   
Opn GGTCAAAGTCTAGGAGTTTCCAG CACCGCTCTTCATGTGAGAGG 
Osterix  TCCCTGGATATGACTCATCCCT CCAAGGAGTAGGTGTGTTGCC 
Pex5 AATGCAACTCTTGTATCCCGAG GGCGAAAGTTTGACTGTTCAATC 
Pex11α TCAACCGCGTGGTTTATTACA CGCCCACCTTTGCCATTTC 
Pex11β GACGAAAGTTGCTACGCCTG GCTCGGTTGAGGTGACTGAC 
Pex11γ CTAGTGGAACAATGCCCCAAC AGGCCATACTGCTTAGTGTAGA 
Pex13 TGGATATGGAGCCTACGGAAA CGGTTAAAGCCCAAACCATTG 
Pex14 GCCACCACATCAACCAACTG GTCTCCGATTCAAAAGAAGTCCT 
Pex19 GCAGCGATGCAAGTTCTCAG CCACTTAACGTCTCCTTTAGGC 
Runx2 CGGTGCAAACTTTCTCCAGGA GCACTCACTGACTCGGTTGG 
Pgc-1α AACCAGTACAACAATGAGCCTG AATGAGGGCAATCCGTCTTCA 
Pparγ GGAAGACCACTCGCATTCCTT GTAATCAGCAACCATTGGGTCA   
RANKL CGCTCTGTTCCTGTACTTTCG GAGTCCTGCAAATCTGCGTT 
3.4.4. Osteoblast protein abundance analysis via Western blots  
3.4.4.1. Whole cell lysate isolation for the western blot analysis of whole 
cell protein abundance  
Total cell lysates of primary osteoblast or ME3T3-E1 cell cultures were isolated 
by using the Cell Lysis Buffer (10X) purchased from Cell Signaling (Cat. #9803) 
according to the standard protocol provided by the manufacturer. Before isolation, 
the medium was removed and the 5×105 cells were washed with PBS and cell 
number was counted. The final osteoblast total cell lysates were retained in 1x 
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cell lysis buffer which was diluted from original 10x cell lysis buffer solution 
containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
EGTA, 1% Triton×100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4 and 1 µg/ml leupeptin, with Milli-Q water, 
containing 10% protease inhibitor mix M (SERVA, Heidelberg, Germany). The 
whole process of cell lysate isolation was done on ice. 
3.4.4.2. Determination of the nuclear protein abundance in the nuclear 
fraction of osteoblast 
After the cell medium had been removed, the osteoblast cells were washed with 
PBS to remove the residues from the medium, thereafter the cells were further 
trypsinized (Sigma, Steinheim, Germany) for 3 min at 37°C. To remove the 
trypsin the detached cells were washed once more with PBS. The nuclear protein 
isolation was carried out with the ProteoJETTM Cytoplasmic and Nuclear Protein 
Extraction Kit purchased from Fermentas LIFE SCIENCES (Cat. #K0311) using 
the standard protocol provided by the manufacturer. All the procedures were 
performed on ice or in the pre-cooled 4° C centrifuge. All solutions used for the 
protein extraction contained 10% protease inhibitor mix M (SERVA, Heidelberg, 
Germany). 
3.4.4.3. Western blots  
Before protein samples were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), the protein concentration of 
each sample was measured with the Bradford Assay using bovine serum 
albumin (BSA)( Roth, Karlsruhe, Germany) as standard (Bradford, 1976). 20 µg 
of the protein sample and 1 µl of dual color and unstained precision plus protein 
Standards® (Bio-Rad, Heidelberg, Germany) were loaded into the blots of a 12% 
SDS polyacrylamide gels. These gels were used for the electrophoresis and 
were made with the ingredients listed in Table.10.  
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Table.10. Solutions for four 12% SDS-polyacrylamide gels with combs with a 
thickness of 1.25 mm  
Resolving gel buffer A 0.4% SDS 1.5 M Tris-HCl, adjusted to pH 8.8 
Stacking gel buffer B 0.4% SDS, 0.5 M Tris-HCl, adjusted to pH 6.8 ， 
Resolving gel (12%) 
 
2 ml of ddH2O, 10 ml of buffer A, 8 ml of 30% acrylamide,15 µl of 
TEMED, 130 µl of 10% APS  
Stacking gel 
 
5 ml of ddH2O, 5 ml of buffer B, 1.25 ml of 30% acrylamide, 15 µl 
of TEMED, 130 µl of 10% APS 
10X Sample buffer 3.55 ml ddH2O, 1.25 ml 0.5 M Tris-HCl (pH 6.8), 2.5 ml 50% (w/v) 
glycerol, 2.0 ml 10% (w/v) SDS, 0.05 % bromophenol blue. 
 Prior to use 50 ml β-mercaptoethanol has was added 
The gel electrophoresis was carried out at stable voltage of 2.4 V/cm2. After the 
sample proteins were separated by SDS-PAGE gel electrophoresis, they were 
blotted onto polyvinylidene fluoride (PVDF) membranes (Millipore, Schwalbach, 
Germany) with a Bio-Rad Trans-Blot® SD semidry transfer cell (Bio-Rad 
München, Germany) for 50 min at 90 mA constant current. Tris-buffered saline 
(TBS) containing 10% non-fat milk powder (Roth, Karlsruhe, Germany) and 0.05% 
Tween-20 (TBST) was used to block the nonspecific protein-binding sites on the 
membrane for 2 hours at RT. The incubation with the primary antibodies was 
carried out at 4° C with no shaking for overnight. After the incubation with the 
primary antibodies, the membranes were washed 5 times for 15 min with 1x 
TBST solution to completely remove residues of the primary antibodies. 
Thereafter, the membranes were incubated with alkaline phosphatase-
conjugated secondary antibodies at RT for 1 hour. The bound antigen antibody 
complexes were visualized by chemiluminescence detection of alkaline 
phosphatase activity with the ImmunoStarTM AP from Bio-Rad (München, 
Germany) as substrate. The chemiluminescence induced light was used for 
exposure with Kodak Biomax MR negative films (Kodak, Stuttgart, Germany). 
The films were developed according to the manufacturer’s protocol. Finally the 
developed negatives were scanned with an AGFA scanner. The membranes 
were re-used to detect different target proteins by stripping and re-probing 
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several times with different primary antibodies. All Western blot analyses were 
performed in triplicates to produce stable repeatable results.  
Table.11. The composition of all buffer solutions used for Western blots 
10×Electrophoresis 
buffer 
250 mM Tris, 2 M glycin + 1% SDS  
20× Transfer buffer Bis-Tris-HCl buffered (pH 6.4) polyacrylamide gel, NuPAGE 
transfer buffer (Invitrogen, Heidelberg, Germany) 
10× TBS 0.1M Tris, 0.15 M NaCl in 1 l ddH2O, adjusted to pH 8.0 
10% Blocking buffer 10 g fat free milk powder in 1x TBST solution  
1% BSA 10 g BSA in 100 ml 1x TBST + 0.05% Tween 20, pH 8.0 
1× Washing buffer 
(TBST) 
10 mM Tris/HCl, 0.15 M NaCl, 0.05% Tween 20, pH 8.0 
Stripping buffer (500 ml) 62.5 mM Tris (pH 6.8), 0.2% SDS, 500 ml ddH2O –  
42°C water bath for 40 min with additional 500 μl 
 β-mercaptoethanol 
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Table.12. Antibdies used for immunofluorescent stainings or Western blots 
Peroxisomal antigens Species AB raised in  Dilution Supplier 
Catalase (CAT), mouse Rabbit, polyclonal 1:2000 
Gift from Denis I. Crane, School of Biomol. Biophys. Sci., Griffith 
Univ., Nathan, Brisbane, Australia 
Peroxisomal biogenesis factor 13 (PEX13p), 
mouse 
Rabbit, polyclonal 1:1000 
Peroxisomal biogenesis factor 14 (PEX14p), 
mouse 
Rabbit, polyclonal 1:4000 
ABC-transporter D3 (ABCD3), mouse Rabbit, polyclonal 1:1000 Gift from Alfred Völkl, University of Heidelberg, Germany 
Mitochondrial antigens 
Superoxide dismutase 2 (SOD2), rat Rabbit, polyclonal 1:1000 Abcam Cat. no ab13533, Cambridge, UK 
Osteoblast-specific antigens 
Osteopontin (OPN), mouse Mouse, monoclonal 1:400 
Santa Cruz Biotechnology Inc., Heidelberg, Germany, Cat. no: sc-
21742 
Runt-related transcription factor 2 (RUNX2), 
mouse 
Rabbit, polyclonal 1:400 
Santa Cruz Biotechnology Inc., Heidelberg, Germany, Cat. no:sc-
10758 
Antibody used for IF staining of Sirt1 KO/WT paraffin embedded newborn mice. 
SIRT1 Rabbit, polyclonal 1:400  Cell Signaling #2028  
Retinoic Acid Receptor Beta (PARβ) Rabbit, polyclonal 1:400 Abcam 53161, Cambridge, UK 
Antibody used for WB loading control 
Histone H3  Rabbit, polyclonal 1:1000 Cell Signaling #9715 
Secondary Antibodies: 
Anti-Rabbit-IgG Alexa Fluor 488 Donkey, polyclonal 1:600 Molecular Probes/Invitrogen, Cat. no: A21206 
Anti-Mouse-IgG Texas Red Horse, polyclonal 1:200 Vertor laboratories, Inc, Burlingame, USA, Cat. no: TI-2000 
Anti-Mouse IgG alkaline phosphatase Goat, polyclonal 1:20,000 Sigma, Steinheim, Germany. Cat. no: A3562 
Anti-Rabbit IgG alkaline phosphatase Goat, polyclonal 1:20,000 Sigma, Steinheim, Germany. Cat. no: A3562 
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3.5 Morphological experiments 
3.5.1. Indirect immunofluorescence stainings of primary osteoblasts  
Primary osteoblasts grown on poly-L-lysine-coated coverslips were rinsed with 
1×PBS (150 mM NaCl, 13.1 mM K2HPO4, 5 mM KH2PO4, pH 7.4) and fixed with 
4% paraformaldehyde (PFA) in PBS (pH 7.4) for 20 min at RT. After fixation, the 
cells were washed three times with PBS. Thereafter, they were incubated for 10 
min in PBS containing 1% glycine and for an additional 10 min in PBS containing 
1% glycin and 0.3% Triton X-100 for permeabilization. After washing the cells 
with PBS, they were incubated for 30 min in PBS containing 1% BSA and 0.05% 
Tween 20 to block the nonspecific protein binding site. Thereafter, the coverslips 
with cells were incubated with primary antibodies overnight at 4°C in a moist 
chamber, followed by washing with PBS 3 times for 5 min the next morning. The 
incubation with the secondary antibodies was performed for 1 hour at RT. Nuclei 
were counterstained with Hoechst 33342 (2 µg/ml) and TOTO 3 iodide 
(Invitrogen). The solutions used in these experiments are described in Table.13. 
Table.13. Solutions for immunofluorescence staining of primary osteoblast 
Perfusion fixative solution  4% PFA in 1X PBS (150mM NaCl, 13.1mM K2HPO4 , 5mM 
KH2PO4 ), pH 7.4 
Glycine (1%) 1g Glycine in 100ml of 1X PBS buffer 
Glycin (1%) + Triton X-
100 (0.3%) 
1g Glycine in 100ml of 1X PBS buffer + 0.3ml Triton X-100 
Blocking buffer- 1% PBSA 
+ 0,05% Tween 20 
To 2g BSA add 200ml of 1X PBS and 100µl of Tween 20 
Mowiol 4-88 solution Overnight stirring of 16.7 % Mowiol 4-88 (w/v) + 80ml of 1X 
PBS, add 40ml of glycerol, stir again overnight; centrifuge at 
15,000 U/min for 1h and take off the supernatant and store at -
20°C 
Anti-fading agent (2.5%)  2.5g N-propyl-gallate in 50ml of PBS and 50ml of glycerol 
Mounting medium  Mowiol 4-88 mixed with anti-fading agent in ratio of 3:1 
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3.5.2. Indirect immunofluorescence staining on Paraformaldehyde-fixed 
paraffin-embedded mouse tissue 
Before 19 days old Pex13 KO/WT mouse fetuses (E18.5) isolated by caesarian 
section from pregnant mice and 0.5 day old new born Sirt1 KO/WT mouse pups 
were used in perfusion fixation. The perfusion fixation was carried out injecting 4% 
depolymerized paraformaldehyde (PFA) containing 2% sucrose in PBS (pH 7.4) 
through left ventricle of the heart using and further fixed by immersion at 4° C 
overnight. The fixed samples were paraffin-embedded (Paraplast, Sigma, St. 
Louis, MO, USA) using a Leica TP 1020 automated vacuum infiltration tissue 
processor(Nenicu et al., 2007). Sections (3 µm) were cut with a Leica RM2135 
rotation microtome. The staining experiments were performed for 3 days as 
Table.14. described: 
Table.14. The experiments procedures of .indirect immunofluorescence staining 
on PFA-fixed paraffin embedded mice tissue sections. 
Time Experiments procedures 
Day 1 
Deparaffinization: sections were placed into 50°C oven (Heraeus, 
Hanau, Germany) for overnight deparaffinization 
Day 2 
1. Deparaffinized with xylene (3x 5min) followed by rehydration in a 
series of ethanol (2x 99%, 96%, 80%, 70%, 50% ethanol, 2 min 
each time).  
2. Antigen retrieval: sections were treated with trypsin and thereafter 
microwaved in TEG buffer (Table.15.) for 5-6min.  
3. Blocking with 4% BSA and 0.05% Tween 20 in PBS at RT for 2 
hours 
4. Sections were incubated with primary antibodies (Table.12.) at RT 
for overnight. 
Day 3 
1. Sections were rinsed with PBS and thereafter  
2. Sections were incubated with the secondary antibodies (Table.12.) 
at RT for hours 
3.  Nuclear staining  
In parallel, negative controls were processed with an addition of PBS buffer 
instead of the first antibodies. Nuclei were visualized with Hoechst 33342 (2µg/ml) 
and TOTO-3 iodide (Molecular Probes/Invitrogen, Carlsbad, USA) for 10 min at 
RT. The solutions were used in these experiments were described in Table.15. 
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Table.15. Solutions for immunofluorescence stainings on PFA-fixed paraffin 
embedded mice tissue section. 
Perfusion fixative solution  4% PFA in 1x PBS (150 mM NaCl, 13.1 mM K2HPO4, 5 mM 
KH2PO4 ), prior to use adjust to pH 7.4 
10X PBS  1.5 M NaCl, 131 mM K2HPO4, 50 mM KH2PO4, prior to use 
adjust to pH 7.4 
Trypsin (0.1%) 0.1 g trypsin in 100 ml of 1x PBS buffer, freshly prepared 
TEG buffer 5 mM EGTA, 0.1 M Tris, pH 9.0 
Blocking buffer-4% PBSA 
+ 0,05% Tween 20 
To 8 g BSA add 200 ml of 1x PBS and 100 µl of Tween 20 
Dilution buffer- 1% PBSA 
+ 0,05% Tween 20 
To 2 g BSA add 200 ml of 1x PBS and 100 µl of Tween 20 
Mowiol 4-88 solution Overnight stirring of 16.7% Mowiol 4-88 (w/v) + 80 ml of 1x 
PBS, add 40 ml of glycerol, stir again overnight; centrifuge at 
15,000 U/min for 1 h and remove the supernatant and store at -
20° C 
Anti-fading agent (2.5%)  2.5 g N-propyl-gallate in 50 ml of PBS and 50 ml of glycerol 
Mounting medium Mowiol 4-88 mixed with anti-fading agent in ratio of 3:1 
Samples were analyzed by confocal laser scanning microscopy (CLSM) with a 
Leica TCS SP2 microscope (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, 
Germany). 
3.5.3. Apoptosis detection by terminal deoxynucleotidyl transferase dUTP 
nick end labeling 
Apoptotic cells in Pex11β WT and KO osteoblast cell cultures were detected by 
the Terminal-deoxynucleotidyl-transferase dUTP nick end labeling (TUNEL) 
using the ApopTag® Fluorescein in situ Apoptosis Detection Kit (S7110 Millipore 
Schwalbach, Germany) according to the manufacturer’s protocol. The basic 
principle of this method is that the 3'-OH ends of double-stranded or single-
stranded DNA breaks can be enzymatically labelled in situ with nucleotides – in 
our case conjugated with digoxigenin (provided in Reaction Buffer 90417 
Millipore) by the terminal deoxynucleotidyl transferase (TdT Enzyme 90418 
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Millipore). Thereafter, the digoxigenin-conjugated nucleotides can be bound by 
the anti-digoxigenin antibody labelled with Fluorescein (90426 Millipore). 
(Product information provided by Millipore for Kit S7110).Negative controls were 
done using 1×PBS (Millipore Darmstadt, Germany) solution instead of the TdT 
Enzyme from this Kit. Positive controls had been pre-treated with DNase l 
(0.1U/µl Deoxyribonuclease I, Amplification Grade Invitrogen Cat.18068-015); 
diluted in DNase I reaction buffer) for 2 min to artificially simulate DNA strand 
break induced apoptosis. 
Primary cell cultures of osteoblasts isolated from three pairs of Pex11β WT and 
KO animals were analyzed for each genotype. For the quantification of the 
apoptosis rates in each cell culture TUNEL-positive cells in 500 randomly 
selected Pex11β WT and KO osteoblast were used. Quantification of TUNEL 
positive cells revealed a pronounced increase in number of apoptotic cells cell 
cultures from Pex11β KO will in comparison to WT mice (P≤0.001). Sample 
images were also analyzed by confocal laser scanning microscopy (CLSM) with 
a Leica TCS SP2 (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany). 
3.5.4. Whole skeleton bone volume and bone density estimation using flat-
panel volumetric computed tomography (fpvCT) of P0.5 mouse pups 
Radiological analysis was applied on new born mouse pups (P0.5) for 
determination of skeleton size, bone volume and density by a flat-panel 
volumetric computed tomography (fpvCT for research only) developed by 
General Electric company (GE). All the techniques for this method were 
developed by Dr. Martin Obert from the Department of Neuroradiology from the 
Justus Liebig University of Giessen and were used in cooperation with our group 
already for scans of adult mice (Obert et al., 2005). The animal scanning and 
VCT image analysis accomplished by Dr. Martin Obert at the Department of 
Neuroradiology at the Justus Liebig University of Giessen. The advantageous 
workstation (Version 4.1, GE Medical Systems, USA) and a LINUX based dual 
2.2GHz processor PC with 4GB RAM were needed for the reconstitution of the 
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data, by which the volume data were visualized as maximum intensity projection 
(Qian, 2010a). The relative bone volume of the scanned mouse pups were 
estimated by Dr. Obert’s developed software (IDL, Version 6.0, RSI, Boulder, CO, 
USA)(Obert et al., 2005). Total of 13 P0.5 mouse pups including all genotypes (3 
of Pex13 WT pups, 5 of Pex13 heterozygous (HE) pups and 5 of Pex13 KO pups) 
were scanned with the VCT. To estimate the partial volume effects, each mouse 
was scanned 3 times with different position rotating on the phantom holder. To 
ensure that with used the scan parameter, data (density volume) are in the linear 
range, plastic straw filled with H2O or aqueous solutions of 50, 100, 200, and 400 
mg K2HPO4 per ml H2O were scanned in parallel. One way ANOVA were used to 
compare the estimated bone volume between each genotype group of Pex13 KO, 
WT and heterozygous.  
3.6. Functional assay of protein DNA binding, biophysical methodology  
3.6.1. Dual-Luciferase reporter gene assay to monitor transcriptional 
activities of markers of bone differentiation RUNX2 and FoxOs, PPARs 
3.6.1.1. Transfection of MC3T3-E1 cells and primary osteoblasts with Dual-
luciferase reporter assay plasmid 
The reporter gene assay experiments were performed by using the Promega 
Dual-Luciferase Reporter Assay System using the manufacturer’s protocol 
Promega (Cat. No: E1910). The Dual-Luciferase Reporter Assay plasmids and 
relevant control plasmids used for the transfection of MC3T3-E1 cells are listed in 
Table.16. 
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Table.16. Plasmids for Dual-Luciferase Reporter Assay 
Plasmid 
name 
Inset gene Cat: Function  Manufacturer  
R19 RUNX2 recognizing 
DNA binding motif 
(Drissi et al., 2000) 
 Luciferase gene 
expression reporter 
assay 
Dr.Hicham 
Drissi* 
 
pGL3-6XDBE 6 copies of daf-16 family 
protein binding elements 
(Ambrogini et al., 2010)  
 Luciferase gene 
expression reporter 
assay 
Prof.Dr. 
Boudewijn 
Burgering# 
pGL3-Basic  Luciferase tag fused 
vector backbone 
E1751 Luciferase gene 
expression reporter 
assay Negative control 
for R19 plasmid 
Promega 
 Mannheim  
 Germany  
 
p4xACO-Luc PPAR-responsive 
element 
Addgene 
16533  
Luciferase gene 
expression reporter 
assay 
Addgene 
Cambridge 
MA USA 
pBV-Luc Luciferase tag fused 
vector backbone  
Addgene 
16539 
Luciferase gene 
expression reporter 
assay Negative control 
Addgene 
Cambridge 
MA USA 
pRL-SV40 Renilla luciferase (Rluc) 
control reporter  
E2231 Dual Luciferase assay 
internal control vectors 
Promega 
 Mannheim  
 Germany  
* Address: University of Massachusetts Medical School, Worcester, MA 01655-0106, USA. 
# Address: University Medical Center, Utrecht, Netherlands, plasmids was kindly provided to my colleague 
Guofeng Qian in our lab. 
All transfections for the luciferase report gene assay were performed with the 
Trans IT® LT-1 transfection reagent purchased from Mirus (MIR2300) according 
to the standard protocol. The luciferase activity assay was carried out 48 hours 
after transfection. 
For the transfection of one well (from a 6-wells plates) 1 µg of Luciferase 
functional plasmid containing the firefly luciferase as reporter gene  was added to 
100 ng Dual Luciferase assay internal control vectors pRL-SV40 (with Renilla 
luciferase) and 4 µl of Trans IT® LT-1 to perform Dual luciferase assays (Vijayan 
et al., 2011). 
3.6.1.2. Sample preparation for Luciferase reporter gene assay 
The transfected MC3T3-E1 cells were cultured in the 6-well cell culture plates for 
48 hours after the transfection and the luciferase assay measurements were 
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performed according to the standard protocol of the manufacturer Promega. The 
growth medium was carefully removed from the cell culture and the cells were 
rinsed with 1x PBS solution to completely remove the rest of the medium. 150 µl 
of 1x strength of luciferase cell culture lysis buffer which had been made by 
mixing 4 volumes of sterile water and 1 volume of the luciferase cell culture lysis 
reagent (CCLR) (5X provided within the kit Promega Cat. No: E1910), was added 
to each well of a 6-well plate and the plates were gently shaken for 10 s to 
ensure that the complete surface was covered with lysis buffer. The total cell 
lysates were collected by scrapping cell culture dishes and transferring the lysate 
into reaction tubes. Before the luciferase activity measurement, all samples were 
incubated on ice for 15 seconds, completely mixed by vigorously vortexing for 15 
s and finally harvested by centrifugation at a speed of 13000× g for 30 s at RT.  
3.6.1.3. Luciferase activity measurement. 
Prior to the measurement, the luminometer (BERTHOLD Technologies Lumat LB 
9507) was primed using the luciferase assay reagent (base line) which was 
mixed completely and equilibrated at RT before use. The sequence of 
measurement was programmed so that the luciferase enzyme activity was read 
by a 2 s measurement delay followed by a 10 s measurement. For each 
measurement, 50 µl of the cell lysate was dispensed into the luminometer tubes. 
In each respective measurement, luciferase activity measurement reading was 
programmed to automatically adjust to work in a linear range. For the output of 
the results, relative light units of luciferase activity were normalized to the values 
per mg protein of the samples. 
3.6.2. Biophysical Methodology to determine cell cycle of primary 
osteoblasts 
The determination of cell cycle using Fluorescence-activated cell sorting applied 
in flow cytometry (FACS) were performed in collaboration with Dr. Carl Bortner in 
the Flow Cytometry Center of Signal Transduction Laboratory, NIEHS, USA. 
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3.6.2.1. DNA Analysis to determine osteoblast cell cycles using Becton 
Dickinson FACSort flow cytometer  
The basic principle of the Becton Dickinson FACSort flow cytometer method is 
utilizing ethanol to fix the osteoblast cells and permeabilize the membrane, 
followed by using Propidium Iodide (PI), which is a DNA-binding fluorochrome 
dye intercalating in the double-helix.(Geary et al., 1982; Harty-Golder and 
Braylan, 1982). The interfering signal from unspecific staining of double-stranded 
RNA can be eliminated by Ribonuclease-A (RNase). 
3.6.2.2. Osteoblast cell culture fixation  
Osteoblasts were cultured in a 6-well cell culture dish as a 75% confluent 
monolayer. After the cells were trypsinized, they were washed and re-suspended 
in 500 µl PBS and chilled well on ice. After 15 min incubation, the cold cell 
suspensions were gently pipetted into clear 12x75 mm polystyrene Falcon tubes 
containing 500 µl of ice cold 70% ethanol which had been pre-cooled and mixed 
by forcing air bubbles through the suspension with plastic pasteur type transfer 
pipettes. The cell suspension was topped off to approximately 2-3 ml with 
agitation by adding additional ice cold 70% ethanol. All mixtures remained on ice 
for another 15 min and the final volume was adjusted to 5 ml with ice cold 70% 
ethanol and the cells were stored at -20° C overnight.   
3.6.2.3. Debris removal  
Before the PI staining step, the debris in the osteoblast cell suspension was 
removed by using Fetal or newborn bovine serum (FBS). 1 ml of ice cold FBS 
was carefully transferred onto the underlay of the Falcon tube and centrifuged at 
300 xg for 3 min. After centrifugation, the liquid phase was carefully removed 
without disturbing the pellet and the attached debris was carefully removed from 
the side of tubes by using a cotton swab. After all debris had been completely 
removed, the pellet was washed once in 3 ml of 1x PBS prior to DNA staining. 
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3.6.2.4. RNA removal and DNA staining  
The cell pellet was re-suspended in 1 ml of 1x PBS containing 1000 units of 
highly purified RNase (Cat # M4265, Promega Corporation, Madison, WI, USA). 
After the suspension was completely mixed by vortexing, the mixture was 
incubated in 37 º C water bath for 15 min for the RNA digestion. Thereafter, the 
tubes were removed from the water bath and the cells were further incubated in 
20 g/ml PI (Cat #4170, Sigma-Aldrich, St. Louis, MO, USA) in this 1x PBS. The 
mixture was completely mixed by vortexing and an incubation at RT for 30 min 
followed. Prior to FACS analysis, the final cell suspensions were pipetted through 
a nylon monofilament mesh screen with 44 micron openings to remove large 
multicellular aggregates common in ethanol-fixed preparations. Thereafter, the 
analysis at the flow cytometer was performed. 
The analysis was carried out using a Becton Dickinson FACSort flow cytometer 
and CELLQuest software (Becton Dickinson Immunocytometry Systems, San 
Jose, CA). Individual cells (7,500 per experimental sample) were selected by 
gating on a PI area versus width dot plot to exclude cell aggregates and debris. 
The cells were excited using a 488 nm argon laser and emission was detected at 
585 nm. The data was analyzed using Modfit software for Mac version 2.0. 
3.6.3. Flow cytometric analysis of ROS in Sirt1 gene shRNA knockdown 
MC3T3-E1 cells  
The principle behind dichlorodihydrofluorescein diacetate (H2-DCFDA) dye 
(Invitrogen C10422) for the detection of the intracellular generation of ROS in 
osteoblast is that the fluorescent ROS-modified H2-DCFDA byproduct 
dichlorofluorescein, which is produced after oxidation and cleavage by cellular 
esterases, can be detected with the flow cytometer. After the osteoblast cells 
were treated with 10 mM of heme oxidase for 30 minutes, 1x106 cells were 
counted and further incubated with medium containing 15 μM H2-DCFDA for 30 
min at 37°C. Before the ROS levels of these osteoblasts were detected with 
FACScalibur flow cytometer, samples were completely washed for three times 
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with 1x PBS at RT. The levels of ROS-oxidized DCFDA fluorescent signals were 
determined with the FACSCalibur flow cytometer. DCF-detectable (FL1-H) 
fluorescent signals were displayed as histograms and ratios of signals versus 
control data were calculated using mean fluorescence intensity (Naidu et al., 
2009; Vijayan et al., 2011). 
3.7 Numerical data presentation and statistical analysis  
The numerical data are presented as bar charts whereby each column of bar 
charts represents the mean value for biological replication of 3 times in each 
group. The error bars of each column represent the values of standard error (SE) 
of each experimental group. Student t-test for paired values and ANOVA test for 
multi-paired values were applied to evaluate the difference in significance 
between and within experimental groups, the significances of differences were 
indicated as *(P≤0.05), **(P≤0.01) and ***(P ≤0.001) compared with the 
corresponding basal value of the WT. 
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4. Results: 
4.1. Part I: The Pex11β gene KO causes peroxisomal dysfunction, resulting 
in osteoblast differentiation delay and severe cell signaling alterations 
4.1.1. Pex11β KO in primary osteoblasts and Pex11β gene knockdown via 
Pex11β shRNA in the MC3T3-E1 cell line 
4.1.1.1. Pex11β gene deficiency primary osteoblasts 
Primary osteoblasts from the calvariae of Pex11β KO mouse pups were isolated. 
To confirm that the Pex11β gene expression was knocked out a qPCR with 
specific primers was performed. On the basis of the mRNA level of the Pex11β 
gene the KO was evaluated. As is shown in Figure.15. the basal value of the 
Pex11β mRNA in Pex11β KO osteoblast is completely diminished than in WT 
primary osteoblasts.  
 
 
Figure.15. The Pex11β gene expression was completely diminished in osteoblast 
cells isolated from Pex11β KO mice. Total RNA of WT osteoblasts and Pex11β KO 
osteoblasts were analyzed for the expression of the Pex11β gene via qRT-PCR.  
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4.1.1.2. Pex11β gene deficiency in MC3T3-E1 cells 
The Pex11β dysfunction in MC3T3-E1 cell line was generated by knocking down the 
Pex11β gene expression with shRNA plasmids with different functional sequences (see 
Table.7.). To evaluate the effects of these plasmids on diminishing the Pex11β gene 
expression level, a RT-PCR and qRT-PCR were performed with the total RNA isolated 
from the MC3T3-E1 cells 48 h after transfection (Figure.16.). With these methods 
strong variation of Pex11β knockdown was observed by using the 4 different 
Pex11β shRNA plasmids. A significantly reduced expression of the Pex11β gene 
could be detected in the MC3T3-E1 cells transfected with plasmid 1,3,4. The 
highest down-regulation was obtained with plasmid 3 whereas the plasmid 2 
induced a Pex11β mRNA stabilization (increased Pex11β band). 
 
 
 
 
 
 
Figure.16. Different Pex11β plasmids show distinct effect on the Pex11β mRNA 
expression level. The expression of the Pex11β gene was significantly diminished 
in Pex11β shRNA transfected ME3T3-E1 cells. A: Total RNA of negative control (NC), 
wild type control (WT) and transfected MC3T3-E1 cells with Pex11β shRNA knockdown 
plasmids were analyzed for the expression of the Pex11β gene by semi-quantitative 
PCR. Four shRNA knockdown plasmids (1-4) were compared with a negative control 
plasmid NC and cells which were not transfected (WT). B: In the best knockdown group, 
total RNAs of the negative control and of MC3T3-E1 cells transfected with the Pex11β 
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gene shRNA knockdown plasmid 3 were analyzed to determine the relative expression 
levels of the Pex11β gene by qRT-PCR (82% knock down).  
4.1.2. The Pex11β gene KO results in dramatically decreasing the 
expression level of the peroxisomal functional enzymes 
It has been known that the abundance of the PEX11β protein can strongly 
influence peroxisome proliferation(Li et al., 2002a). To determine the effects of 
Pex11β knockout on the expression of other peroxisome biogenesis genes, 
qPCRs were performed with the samples of total RNA isolated from Pex11β 
WT/KO primary osteoblast and the Pex11β knockdown MC3T3-E1 cells 
(Figure.17.and 18.).  
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Figure.17. The expression levels of peroxisome biogenesis genes are not 
significantly changed compared to the WT levels, whereas the PMP protein was 
down regulated in Pex11β KO osteoblast cells and Pex11β shRNA knockdown 
MC3T3-E1 cells. A: Total RNA of WT and Pex11β KO primary osteoblasts were 
analyzed for the expression level of important peroxisome biogenesis genes via qRT-
PCR. B: Total RNA of Pex11β gene shRNA knockdown plasmids and corresponding 
control plasmid transfected MC3T3-E1 cells were analyzed to determine the expression 
levesl of important peroxisome biogenesis genes via qRT-PCR. 
The results of the qRT-PCR demonstrate that the expression levels of most of 
the peroxisome biogenesis genes are not altered significantly via the chronic 
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causal KO (Figure.17.A) and ones slightly with the acute knockdown (Figure.17.B) 
of Pex11β. Most of the changes in the gene expression occurred in Abcd3 which 
encodes a membrane transporter that functions as a channel for metabolic β-
oxidation substrates, such as VLCFA. This result suggests the peroxisomal β-
oxidation functions possibly may have been interfered by Pex11β gene deletion.  
 
 
Figure.18. The gene expression of most peroxisomal enzyme is significantly 
decreased in Pex11β KO osteoblast and Pex11β shRNA knockdown MC3T3-E1 
cells. A: Total RNA of WT control and Pex11β KO osteoblasts were analyzed to 
determine the expression levels of important peroxisomal antioxidant and β-oxidation 
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enzyme genes by qRT-PCR. B: Total RNA of Pex11β gene shRNA knockdown plasmids 
and corresponding control plasmid transfected MC3T3-E1 cells were analyzed to 
determine the expression levels of important peroxisomal antioxidant and β-oxidation 
enzyme genes by qRT-PCR. 
The qRT-PCR results revealed that the gene expression levels of fatty acid β-
oxidation enzymes, especially Acox1 and Acox2, were significantly decreased in 
the Pex11β KO osteoblast (Figure.18.A). In the MC3T3-E1 cell line acute 
knockdown also the mRNAs for most peroxisomal β-oxidation enzymes are 
reduced whereas in the chronic Pex11 β knock out only Acox1 and Acox2 are 
diminished. Furthermore, the down-regulation of β-oxidation enzymes in Pex11β 
KO osteoblast also has been confirmed on the protein level via western blot 
which were previously performed in our laboratory: in particular the Thiolase, as 
well as the lipid transporter ABCD3 in the peroxisomal membrane were down-
regulated (Qian, 2010a). Therefore, the β-oxidation function of the peroxisome 
was disturbed through the Pex11β gene deletion in osteoblast, which probably 
results in the accumulation of lipids together with their metabolic and toxic effects 
in Pex11β KO osteoblast. 
4.1.3. Osteoblast differentiation and maturation were severely altered in the 
primary osteoblast cells culture with Pex11β KO  
Previously, it has been shown that primary osteoblast with a Pex11β KO are 
much less matured compared to WT osteoblast. We have observed that the 
typical middle stage of osteoblast maturation marker OPN and the later stage 
osteoblast cell maturation marker BGLAP (Tanaka et al., 2012) are reduced 
present in Pex11β KO osteoblast compared to the WT osteoblast, both in vitro 
and vivo. More interestingly, in further experiments, we found that the 
differentiation and maturation delay caused by Pex11β deficiency mainly 
occurred in the later stage of pre-osteoblast, mature osteoblast, as the following 
figure 19 shows. The expression levels of osteoblast differentiation marker genes 
can be used for indicating progressing steps of osteoblast differentiation and 
maturation. Our group also has found that the middle stage and maturation 
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marker protein OPN and BGLAP were decreased in Pex11β KO osteoblast (Qian, 
2010a), whereas the osteoblast progenitor marker Col1a1 and Col1a2 gene 
expression levels were not significantly changed in Pex11β KO osteoblast 
compared to WT. Therefore, the delay in Pex11β KO osteoblast starts only after 
the osteoblast progenitor stage at the maturation stage of early-osteoblast. 
The delay of osteoblast differentiation might not be the only reason why Pex11β 
KO animal exhibit reduced ossification and bone value. Therefore we have 
investigated whether there are other abnormal phenotypes in Pex11β KO 
osteoblast that might affect ossification(Qian, 2010b). 
 
Figure.19. The Pex11β KO osteoblast exhibit a delay in the differentiation process 
indicated by the expression level of osteoblast differentiation stage markers. A: 
Total RNA of WT and Pex11β KO osteoblast were analyzed to determine the 
expression levels of osteoblast progenitor markers Col1a1 and Col1a2 via qRT-PCR; B: 
Total RNA of Pex11β KO osteoblast and WT were analyzed to obtain the expression 
levels of the pre-osteoblast marker Runx2, mature osteoblast marker Ibsp and osteocyte 
marker Osterix via qRT-PCR. 
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4.1.4. The DNA binding functions of key nuclear receptors regulating the 
osteoblast differentiation and function were significantly altered in Pex11β 
KO osteoblasts 
4.1.4.1. The Pex11β shRNA knockdown in MC3T3-E1 cell culture 
coordinates the results of primary osteoblast cells and lead to significant 
decrease of differentiation and maturation 
To further confirm the results of differentiation delay of Pex11β KO osteoblast, 
the model of Pex11β shRNA knockdown in MC3T3-E1 cell was used. 
The .expression levels of osteoblast differentiation markers of the early middle 
and maturation stage (Figure.20.) are dramatically decreased in the Pex11β 
shRNA knockdown in MC3T3-E1 cells in the very similar manner as the ones in 
Pex11β KO primary osteoblast (Figure.19.). Therefore, this cell line was used to 
measure gene transcriptional activity using the luciferase reporter gene assays 
(Figure.21.-23). 
 
Figure.20. The Pex11β shRNA knockdown in MC3T3-E1 cells also exhibit a 
delay in the differentiation process indicated by the expression level of osteoblast 
differentiation stage markers. Total RNA of MC3T3-E1 cells transfected with Pex11β 
gene shRNA knockdown and control plasmids were analyzed to determine the 
expression levels of the pre-osteoblast marker Runx2, mature osteoblast marker Ibsp 
and osteocyte marker Osterix via qRT-PCR. The columns are the mean ± SE for n=3 
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experiments in each group, student t test for paired values compared with the 
corresponding basal value of the WT/control was used. 
4.1.4.2. Significant decrease of the DNA binding activity of FoxOs in 
osteoblast with Pex11β shRNA knockdown.  
Previous research on the skeleton revealed the importance of the regulator 
forkhead box1 (FoxO1) which is indeed a regulator of redox balance in 
osteoblast (Almeida et al., 2009; Ambrogini et al., 2010; Tanaka et al., 2012). 
FoxO1 belongs to the winged helix/forkhead family of transcription factors. which 
share a highly conserved 110-amino-acid DNA-binding domain, also known as 
forkhead box or winged–helix domain (Obsil and Obsilova, 2011). This balance 
was clearly decreased in Pex11β KO in osteoblast; in particular, the level of 
FOXO1 protein was reduced in Pex11β KO osteoblasts compared with WT(Qian, 
2010a). 
 
Figure.21. The FoxO protein DNA binding capability was slightly decreased in 
Pex11β shRNA knockdown ME3T3-E1 cells. ME3T3-E1 cells after Pex11β shRNA 
knockdown and control cells were transfected with the pGL3-6xDBE FoxO response 
element luciferase reporter plasmids (Ambrogini et al., 2010). 24 hours after transfection, 
cell extracts were collected and assayed for luciferase activity.  
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4.1.4.3. Increase of the activity of the PPAR response element (PPRE) in 
Pex11β KO osteoblast compared with WT 
Previous research in our lab had revealed that the PPARγ protein level was 
dramatically increased in Pex11β KO osteoblast which was determined by 
Western blots using the whole cell lysate of Pex11β KO and WT osteoblast (Qian, 
2010a). Activation of the PPARγ can result in the differentiation of the 
mesenchymal stem cells into adipocytes instead of the osteoblast progenitors 
(Almeida et al., 2009) and this activation can be triggered by the binding of PPAR 
and agonists. The activated PPARγ can bind the PPRE to switch on the specific 
gene expressions that regulate the mesenchymal stem cell differentiation 
(Almeida et al., 2009; He et al., 1999). 
 
Figure .22. The PPARs response element (PPRE) is considerably more activated in 
Pex11β shRNA kockdown ME3T3-E1 cells compared to the control group (WT). 
ME3T3-E1 Pex11β shRNA knockdown cells and control cells were transfected with 
luciferase reporter vectors (plasmid p4xACO-Luc).24 hours after the transfection; cell 
extracts were collected and assayed for luciferase activity.  
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4.1.4.4. Significant decrease of the Runx2 DNA binding activity in Pex11β 
KO osteoblast 
RUNX2 is an important transcription factor in osteoblast progenitors, pre-
osteoblasts and even in chondrocytes by regulating the expression of several 
bone and cartilage genes and is essentially required for the bone formation in 
vivo (Drissi et al., 2000). The RUNX2 DNA binding function is based on the 
affinity to specific motifs localized in the promoter region of some important 
genes regulating bone cell differentiation and bone formation, including Runx2 
itself thus being self-regulated in part by a “negative feedback (Drissi et al., 2000). 
RUNX2 determines the lineage of osteoblast from multipotent mesenchymal cells, 
enhances osteoblast differentiation at an early stage, and inhibits osteoblast 
differentiation at a late stage (Komori, 2002). In the Pex11β shRNA knockdown 
osteoblast, RUNX2 DNA binding capability was considerably altered (Figure.23.). 
A decrease of approximately 20% in the reporter gene activity was observed and 
later stage differentiation was delayed in the Pex11β shRNA knock down cells. 
 
Figure.23. The Runx2 response element activity is decreased in Pex11β 
shRNA knockdown ME3T3-E1 cells. ME3T3-E1 Pex11β shRNA knockdown 
and control cells were transfected with the luciferase reporter vector (plasmid 
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R19 as described in “Materials and Methods”). 24 hours after the transfection, 
cell extracts were collected and assayed for luciferase activity.  
4.1.5. Significantly higher amount of apoptosis of primary Pex11β KO 
compared to WT osteoblasts. 
To quantify the apoptotic osteoblast, a TUNEL assay was performed using 
Pex11β KO/WT primary osteoblast. The number of apoptotic osteoblast in the 
Pex11β KO model was significantly higher in comparison to the WT (Figure.24.). 
The TUNEL staining results revealed that apoptosis was considerably increased 
in the Pex11β KO osteoblast cell culture, which suggests that the osteoblast 
function might be disturbed strongly by possibly increasing oxidative stress due 
to peroxisome dysfunction in Pex11β KO osteoblast cells. Furthermore, this 
result also suggests that some critical cellular signaling pathways that attenuate 
to the osteoblast differentiation and maturation, such as FoxOs and PPAR 
signaling pathways might be also altered by the increase in oxidative stress in 
Pex11β KO osteoblast. Therefore, several functional assays to determine the 
altered activity of these signal pathways were performed by using Pex11β the 
shRNA knockdown MC3T3-E1 cell model. 
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Figure.24. Increased number of apoptotic osteoblast present in primary Pex11β 
KO osteoblast cell culture compared to WT. Apoptotic cells in Pex11β WT and KO 
osteoblast cell cultures were detected using the ApopTag® Fluorescein in situ Apoptosis 
Detection Kit (S7110 Millipore GmbH, Schwalbach, Germany) by direct TdT-mediated 
dUTP-biotin nick end labeling (TUNEL), utilizing an anti-digoxigenin antibody conjugated 
with Fluorescein molecule according to the manufacturer’s protocol (A and D). The 
number of apoptotic nuclei was (right picture G) increased in Pex11β KO cell cultures (D) 
in comparison to the WT cell cultures (A). B and E: Positive controls (PC) had been 
pre-treated with 0.1U/µl DNase l for 2 min to artificially induce DNA strand break. 
C and F: Negative controls (NC) were done using 1×PBS solution instead of the 
TdT Enzyme from this Kit. (see section 3.5.3) G: Osteoblasts isolated from 3 pairs of 
Pex11β WT and KO animals were analyzed. For the quantification of the apoptosis rates 
in each of the 3 cell cultures, TUNEL-positive cells in 500 randomly selected Pex11β WT 
and KO osteoblasts were counted. Quantification of TUNEL positive cells revealed a 
pronounced increase in the number of apoptotic cells in Pex11β KO cell culture in 
comparison to WT cells (P<0.001). Bars represent 50 µm. 
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4.1.6. Strong disruption of the cell cycle and proliferation rate in Pex11β KO 
osteoblast  
Previous results also showed the weaker transcriptional function of FoxO in 
Pex11β KO osteoblast cells (Figure.21.) (Sanchez et al., 2014; Sang et al., 2014). 
Therefore, it could be hypothesized, that the cell cycle of Pex11β KO osteoblast 
cells should be altered compared to the WT. Wherefore we applied a FACS 
experiment. 
The FACS results of cell revealed that the S-phase and the G2/M phase of the 
Pex11β KO osteoblasts were extended. Statistically, more Pex11β KO osteoblast 
in cell culture were in the S-phase and the G2/M phase and less in the G1 phase 
compared to the WT cells in cell culture. However, when the osteoblasts were 
cultured with differentiation enhancing medium and osteoblasts differentiation 
was promoted, even less Pex11β KO osteoblasts were found in the S-phase 
started to decrease dramatically after 4 and 7 days of induction compared to WT 
osteoblast (Figure.25.) 
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Figure.25. FACS analysis of cell cycle of Pex11β KO in comparison to WT 
osteoblasts. Percentage of cells in different phase are indicated below the graph. 
Cell cycles of Pex11β KO osteoblast were strongly altered compared to Pex11β WT 
osteoblasts, and this alteration was diminished when the osteoblasts were cultured in 
osteoblasts differentiation enhance medium from day 0 (induction start). 
By numeric analysis, the reason for the decrease in the number of Pex11β KO 
osteoblasts in the S-phase appears to be because of an interference in the G2/M 
phase checkpoint by the Pex11β gene deletion and because more Pex11β KO 
osteoblasts in the S-phase went through the checkpoint and were arrested in the 
G2 phase. The checkpoint at the boundary between the G2 and M phase of the 
cell cycle (G2/M) can regulate entry into mitosis. In many organisms, this 
checkpoint surveys DNA damage and cell size and is controlled by both the 
activation of mitotic cyclin-dependent kinases (Cdks) and the inhibition of an 
opposing phosphatase, protein phosphatase 2A (PP2A). Misregulation of mitotic 
entry can often lead to oncogenesis or cell death (Han et al., 2010). 
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4.2. Part II: The Pex13 KO caused peroxisomal biogenesis defect result in 
the interference with the antioxidative response, osteoblast differentiation 
and maturation 
4.2.1. Pex13 KO mice (P0.5) exhibit a delay in the ossification process  
Previous results of a doctoral student in the Baumgart-Vogt group showed, that 
Pex13 KO mice develop an obvious bone phenotype much later than Pex11β KO 
mice. Indeed, E19 Pex11β KO mouse fetuses display defects in ossification and 
skeletal deformation (Qian, 2010a), whereas E19 Pex13 KO mouse fetuses do 
not yet display significant differences in ossification and skeletal formation. 
Therefore we analyzed older P0.5 Pex13 KO/WT mouse pups which were used 
to determine the bone development. The results are depicted in Figure 26. With 
the help of the VCT analysis, it was shown that in comparison to Pex13 WT and 
Pex13 heterozygous (HTZ) mice, the skeletal differentiation of Pex13 KO mice 
was altererd, displayed by much smaller size of the pups and significantly less 
bone volume due to delayed ossification. In particular, the size of the skull in 
Pex13 KO mice is relatively smaller and the long bones such as tibiae, ribs, 
femora are shorter, indicating both intramembranous and endochondral 
ossification defects in Pex13 KO mice (Figure.26.).  
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Figure.26. Pex13 KO pups are smaller; the bone volume is significantly decreased 
and the ossification delayed compared to WT pups. A: Newborn Pex13 KO pups (P 
0.5) were scanned with a VCT. Significant difference are observed by comparing 
ossification center in the Pex13 KO animals (e.g. in ossification coxal and paws or skull). 
B: Relative bone volume (g/cm3) estimated via VCT scanning revealed that the bone 
volume of the Pex13 KO mice is significantly reduced in comparison to Pex13 WT and 
Pex13 HTZ mice. 
B 
A 
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Compared to Pex11β KO mice, it seems that the ossification defect of Pex13 KO 
mice is initiated in a later stage of development, probably caused by a decreased 
capability of osteoblast mineralization. Therefore, a minimization staining 
experiment was performed using osteoblast isolated from Pex13 KO mice in 
compared to WT mice. The following Figure.27. depicts the results. The 
differentiation enhancing medium can stimulate and speed up the pre-osteoblast 
differentiation to mature state osteoblast with full functional mineralization 
capacity which is indicated by the synthesis and secretion of osteocalcin (BGLAP) 
protein (Figure.28.D). The mineralization staining revealed that less calcium 
hydroxyapatite containing osteoid was formed in the Pex13 KO cells compared to 
Pex13 WT cells under the same cell culture conditions. This result suggests that 
differentiation and maturation processes are significantly delayed in Pex13 KO 
osteoblast. 
 
 
 
 
 
 
 
Figure.27. Mineralization staining was performed to detect the synthesized matrix 
at various stages of osteoblast differentiation in Pex13KO versus WT osteoblasts 
in cell culture. The differentiation medium was added to the cell culture starting at day 
10 after the primary osteoblast isolation. Osteoblasts were cultured for 9 days (28-10=18) 
in the differentiation enhancing medium, calcium-rich deposits can be stained with 
Alizarin red S staining to evaluate the progress of bone formation of mature state 
osteoblasts in cell culture (Gregory et al., 2004). The Pex13 KO osteoblast cell culture 
was stained less by Alizarin red S.  
Pex13 +/+ 
 
 
 
Pex13 -/- 
Mineralization  
Induction (Days)  10       13             16            19         22          25          28 
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To further confirm the delay of Pex13 KO osteoblast differentiation, the gene 
expression level of osteoblast differentiation and maturation markers were 
determined with qRT-PCR (Figure.28.). Interestingly, compared to the delay in 
differentiation of Pex11β KO osteoblasts starting at middle stage, the 
differentiation delay of Pex13 KO osteoblast started from the osteoblast 
progenitor stage, which was the earliest stage of osteoblast isolated from the 
calvariae of mouse pups of Pex13 KO. Throughout the lifespan of osteoblast until 
the osteocyte stage, the differentiation process is significantly delayed. 
Specifically, in the pre-osteoblast stage and middle stage of osteoblast 
differentiation compared to WT, the delay is indicated by a strongly reduced gene 
expression level of osteoblast differentiation stage markers for osteoblast 
progenitors markers (A) Col1a1 and Col1a2, (B) pre-osteoblast markers Alp and 
Runx2, (C) middle stage osteoblast differentiation markers Ibsp and Opn, (D) 
osteoblast maturation markers Osterix and Bglap (Figure.28.). 
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Figure.28. Delayed differentiation and maturation of osteoblast from calvariae of 
Pex13 KO mice. Total RNA of wild type (WT) control and Pex13 KO osteoblast was 
analyzed to determine the expression levels of mRNA for osteoblast progenitor and 
mature osteoblast markers. A: osteoblast progenitor markers Col1a1 and Col1a2; B: 
Pre-osteoblast markers Alp and Runx2; C: osteoblast middle stage marker Opn and 
Ibsp; D: osteoblast maturation markers Osterix and Bglap via qRT-PCR. 
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4.2.2. Peroxisomal biogenesis genes and the osteoblast differentiation 
process were disturbed 
The expression levels of peroxisome biogenesis genes and metabolic matrix 
enzymes genes are decreased in Pex13 KO osteoblast. It has been observed 
that the Pex13 KO mice lack morphologically intact peroxisomes and display a 
defect in the import of matrix proteins containing either type 1 or type 2 targeting 
signals (Maxwell et al., 2003). To determine, how peroxisome biogenesis and 
metabolic genes are altered by the Pex13 gene deletion in osteoblast, qPCRs 
were performed to analyze the expression levels for peroxisome related genes. 
The results are depicted in Figure.29. The expression levels of almost all 
peroxisomal biogenesis (except for Pex11α) and functional enzyme genes were 
dramatically reduced in Pex13 KO osteoblast compared to WT.  
 
 
 
 
 
 
 
 
92 
 
 
 
Figure.29. Peroxisome related gene expression is strongly reduced in Pex13 KO 
osteoblast. A: Total RNA of WT control and Pex13 KO osteoblasts was analyzed to 
determine the expression levels of important peroxisomal biogenesis genes and B: 
genes of peroxisomal matrix enzyme genes by qRT-PCR. 
4.2.3. The oxidative response is stimulated by oxidative stress in the bone 
cells of Pex13 KO mice due to peroxisomal dysfunction 
Alteration of mitochondria morphology and indication for oxidative stress has 
been described in the Pex5 KO mouse model by Baumgart and colleagues 
(Baumgart et al., 2001). However, no information on alteration of mitochondria 
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due to peroxisomal knockout was described in osteoblast or other bone cells. A 
nice indicator of mitochondrial oxidative stress is the elevation of SOD2, which 
has been exclusively localized to mitochondria, by our group, in comparison to 
previous report that allocated this enzyme also to the peroxisomal 
membrane(Singh et al., 1999) 
The excellent anti-SOD2 antibody was used in this thesis to detect potential 
activation of the antioxidative response in mitochondria of Pex13 KO osteoblast 
(Figure.30.). 
 
Figure.30. The mitochondrial antioxidant enzyme SOD2 is increased in Pex13 KO 
osteoblast. Double immunofluorescence labelling of paraffin sections of the mandibular 
bone of Pex13 KO and Pex13 WT mouse sections with antibodies against SOD2 and 
OPN. The red fluorescence (OPN) indicates the differentiated osteoblast (indicated by 
the arrows). Strongest green fluorescenct (SOD2) are mitochondria more prominent in 
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Pex13 KO osteoblast. In the WT animal SOD2 staining and mitochondria are most 
prominent in osteoclast (OC), whereas osteoblasts are hardly stained for SOD2. Bars 
represent 50 µm. 
Under normal conditions, SOD2 in osteoclast mitochondria are most labelled, 
and osteoblasts only show minor labelling. Indeed, highly elevated SOD2 levels 
were found in the osteoblast of Pex13 KO mice. The elevation of SOD2 might be 
explained by a higher ROS production within the mitochondria or a higher 
cytoplasm ROS level due to the Pex13 KO. 
To further test this hypothesis, an experiment with the induction of the antioxidant 
N-Acetyl-Cysteine (NAC) to the cell culture was designed. In particular, this rescue 
experiment was designed to the antioxidant N-Acetyl-Cysteine (NAC) to treat the 
Pex13 KO osteoblast cell cultures in order to eventually compensate the 
response effects caused by increased oxidative stress in Pex13 KO osteoblast 
(Figure.31.).  
 
 
 
 
 
 
Figure.31. The reaction to N-Acetyl-Cysteine is different in Pex13 KO and WT 
osteoblast. Oxidative stress in Pex13 KO osteoblast can be partially rescued by 
treatment with antioxidant drug N-Acetyl-Cysteine (NAC). Total RNA was isolated 
from wild type (WT) control and Pex13 KO osteoblast cell cultures which were treated 
with osteoblast medium containing 5 mM N-Acetyl-Cysteine (NAC) for 3 days. The total 
RNA was analyzed to determine the expression levels of mRNA for A: peroxisomal 
 
 
A B C 
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membrane transporters Abcd1 and Abcd3; B: antioxidative enzymes catalase, Heme 
oxygenase 1 (HO-1) and its regulator Nuclear factor (erythroid-derived 2)-like 2 (NRF2); 
C: important redox-sensitive transcriptional regulator of the FoxO family (members 
Foxo1, 3 and 4) in bone by semi-quantitative polymerase chain reaction (RT-PCR). 
Considering the peroxisomal markers, the expression level of peroxisomal 
membrane protein ABCD1 were decreased in Pex13 KO osteoblast, in both NAC 
treated and untreated situation. This result indicates that the presence of 
peroxisomes was decreased in Pex13 KO osteoblast in this cell culture with drug 
treatment model (Figure.31.A). Interestingly, the expression level of 
peroxisomam antioxidative enzyme catalase was increased in the Pex13 KO 
osteoblast and dramatically reduced when the ROS molecules were trapped by 
NAC drug. Whereas, antioxidant response regulator NRF2 expression level was 
decreased in Pex13 KO and also decreased with NAC treatment in both Pex13 
KO and WT osteoblast. The NFF2 regulating antioxidant enzyme HO-1 
expression were much decreased in NAC treated Pex13 KO osteoblast, 
compared with the one in NAC treated Pex13 WT osteoblast (Figure.31.B). 
Furthermore, within the 3 isoforms existing in osteoblast, FoxO1 expression level 
is much higher in Pex13 KO osteoblast and also dramatically increased in NAC 
treated Pex13 KO osteoblast (Figure.31.C). FoxO1 within the FoxO family is 
indeed an important regulator of redox balance in osteoblast and the catalase 
gene baseline transcription could be activated by FoxOs through oxidative stress 
and lipid peroxidation (Almeida et al., 2009; Ambrogini et al., 2010; Tanaka et al., 
2012).  
4.2.4. The DNA binding activity of the Runx2 nuclear receptor which 
regulates osteoblast differentiation and function was significantly 
attenuated in primary osteoblast of Pex13 KO mice 
As shown earlier in the Pex11β Chapter (4.1.5.4), the RUNX2 DNA binding 
capability was demonstrably altered, approximately 20% decrease in Pex11β 
shRNA knockdown cells compared to control cells (Figure.23.) and only later 
stage differentiation was seriously delayed in the Pex11β KO osteoblast 
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compared with WT (Figure.19.).However, in the Pex13 KO osteoblast, the 
RUNX2 DNA transactivation capability was decreased around 70% (Figure.32.) 
and the most severe differentiation delay occurred in the osteoblast-progenitor, 
early pre-osteoblast and middle stage of osteoblast differentiation in Pex13 KO 
(Figure.28.) (Komori, 2008). 
 
 
Figure.32. The activity of the Runx2 response element is decreased in Pex13 KO 
primary osteoblast. Pex13 KO and WT primary cells were transfected with the 
luciferase reporter vector plasmid R19. 24 hours after transfection, cell extracts were 
collected and assayed for luciferase activity.  
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4.3. Part III: SIRT1 deficiency impairs peroxisomal functions and promotes 
pre-mature differentiation of pre-osteoblasts and abnormal bone 
development in mice  
The results in Figure.36. and 44. have been published in Molecular Cell with the 
pubmed ID PMID: 25155613 
Shuang Tang, Gang Huang, Wei Fan, Yue Chen, James M. Ward, Xiaojiang Xu, Qing 
Xu, Ashley Kang, Michael W. McBurney, David C. Fargo, Guang Hu, Eveline 
Baumgart-Vogt, Yingming Zhao, and Xiaoling Li  (2014) “SIRT1-mediated deacetylation 
of CRABPII regulates cellular retinoic acid signaling and modulates embryonic stem cell 
differentiation” Molecular Cell. 2014 Aug 20. pii: S1097-2765(14)00604-2. doi: 
10.1016/j.molcel.2014.07.011. 
The mammalian SIRT1 has been very well studied and it has been understood to 
be implicated in a variety of metabolic processes by its functions of central 
sensor of nutrient and energy metabolism (Li and Kazgan, 2011). The variety of 
metabolic activities of mammalian are modulated by activated SIRT1 through 
either direct protein deacetylation or indirect chromatin remodeling (Li and 
Kazgan, 2011). Since the SIRT1 control lipid metabolism via PGC1α and 
regulates PPAR functions and subsequently peroxisome genes are regulated by 
these nuclear receptors (Li, 2013), it can be believed vice-versa that the SIRT1 
activity could possibly be altered by peroxisomal dysfunction caused by Pex11 or 
Pex13 gene deletions. Therefore, the levels of Sirt1 gene expression and SIRT1 
protein in Pex11β and Pex13 KO animal models were determined with qPCR, 
WB and IF staining. 
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4.3.1. SIRT1 protein level is altered in primary osteoblast with peroxisomal 
deficiency 
 
 
 
 
 
Figure.33. The SIRT1 protein content Pex11β KO primary osteoblasts, in particular 
in the nuclear fraction, is much lower than in WT osteoblasts, while there is no 
significant difference in Sirt1 gene expression. A: Total RNA of WT control and 
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Pex11β KO osteoblast were analyzed to identify the expression level of the Sirt1 gene 
expression via qPCR. B: Comparative Western blot analyses to examine the SIRT1 
protein content in total osteoblast cell lysate and the nuclear fraction. C: 
Immunofluorescence preparation to determine the SIRT1 protein content in Pex11β KO 
and WT primary osteoblasts Bars represent 50μm. 
From the literature it is known that SIRT1 plays several roles in pathways that are 
related to bone development and remodeling, in particular, deacetylation and 
activation of -catenin, a Wnt signaling molecule involved in the self-renewal and 
differentiation of mesenchymal stem cells (Ling et al., 2009). Previous research 
in our laboratory, also revealed that the delay of osteoblast differentiation was 
associated with an increase in oxidative stress and the cytoplasmic translocation 
of -catenin caused by canonical Wnt signaling diminishment in Pex11β KO 
osteoblast (Qian, 2010a).  
 
 
Figure.34. The Sirtuin genes including Sirt1 expression are significantly lower in 
Pex13 KO osteoblast compared to WT. A: RT-PCR results exhibit the alterations of 
mRNA levels of Sirtuin genes in Pex13 KO osteoblasts. B Total RNA of Pex13 KO/WT 
osteoblast was analyzed for the expression level of the Sirt1 gene by qRT-PCR. 
In contrast to Pex11β KO osteoblast, but also in osteoblasts with PEX13 
deficiency the Sirt1 mRNA was significantly downregulated. In these knockout 
cells, also the mRNA expression of other Sirtuin family members was analyzed. 
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Interestingly, especially the mitochondrial Sirtuin deacetylase mRNAs, the one 
for the Sirt 3, 4 and 5, were down-regulated in Pex13 KO osteoblasts 
(Figure.34.A) (Haigis and Sinclair, 2010). Altogether suggests increase of 
mitochondrial stress in Pex13 KO osteoblast cells and severe interferences with 
general acetylation of sirtuin substrates due to the peroxisomal deficiency. To 
summarize, both the SIRT1 protein nuclear region downregulation in the Pex11β 
KO osteoblast (Figure.33.) and the dramatically down-regulated Sirt1 gene 
expression level in Pex13 KO osteoblast (Figure.34.) may play important roles in 
the dysregulation of osteoblast differentiation and ossification defect due to 
peroxisome deficiency. Fortunately, a Sirt1 KO animal was available for us 
through collaboration with the group Xiaoling Li at NIEHS USA. Therefore, in the 
following it was analyzed whether the Sirt1 KO would also have an effect on the 
peroxisomal compartment and influence bone differentiation. 
4.3.2. Sirt1 KO in primary osteoblast and Sirt1 ShRNA stable knockdown in 
the MC3T3-E1 cell line 
Two osteoblast cell culture models were used to analyses the effect of a Sirt1 
defect on the osteoblast differentiation and peroxisome composition. Primary OB 
isolated from calvariae of P0.5 Sirt1 KO/WT mice and Sirt1 shRNA knockdown in 
MC3T3-E1 cells. The qRT-PCR and Western blot analysis verified the complete 
deletion of the Sirt1 gene in primary osteoblasts and the decrease of SIRT1 
protein abundance in MC3T3-E1 cells transfected with Sirt1 shRNA. (Figure.35.).  
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Figure.35. Verification of the absence of Sirt1 in primary osteoblast and SIRT1 
knockdown in shRNA transfected MC3T3-E1 cells. A: Total RNA of WT control and 
Sirt1 KO osteoblast was analyzed for the expression level of the Sirt1 level by qRT-
PCR. B: Comparative Western blot analyses to examine the SIRT1 content in whole cell 
lysate of Sirt1 KO and WT primary osteoblast. The abundance of the Histone H3 was 
used as loading control. C: Comparative Western blot analyses to examine the SIRT1 
protein content in whole cell lysate of Sirt1 shRNA knockdown and control MC3T3-E1 
cells. 
In additional to biochemical experiments, the Sirt1 KO was also confirmed in the 
immunofluorescence preparation of paraformaldehyde fixed paraffin-embedded 
tissue section of bone. Figure. 36. reveals the high specificity of the anti-SIRT1 
antibody and clearly shows high level staining for SIRT1 in osteoblast of WT 
animal and no staining in Sirt1 KO animal. 
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Figure.36. The SIRT1 protein is highly abundant in bone tissue of WT mice and 
absent in Sirt1 KO mice compared to WT. Paraffin sections of Sirt1 KO and WT P0.5 
mouse pups were labeled with fluorescence-labelled antibodies against the endogenous 
SIRT1 protein (green). The pictures were taken at the calcified region bone matrix (BM) 
of the diaphysis of the femur in long bones isolated from Sirt1 KO and WT P0.5 mouse 
pups. These results were published in collaboration study with X. Li (NIEHS, North 
Carolina, USA) Figure 7 B of Tang et al, Mol Cell 2014. Bars represent 50 µm. 
4.3.3. Differentiation and maturation of osteoblasts were promoted from the 
pre-osteoblast stage in Sirt1 KO osteoblast  
As mentioned in a previous chapter (see 1.3.2.1), the expression levels of 
osteoblast differentiation stage markers are important parameters to evaluate the 
progression of osteoblasts differentiation. By using these parameters, the 
progress of differentiation of Sirt1 KO osteoblast compared to WT was 
determined with qRT-PCR. Apparently, in comparison to peroxisome deficient 
knockout, the Sirt1 KO osteoblast contain higher levels of mRNA of middle and 
later stage bone markers. 
 
 
103 
 
 
 
 
 
Figure.37. SIRT1 deficiency results in pre-mature differentiation pattern of OB. 
Total RNA of WT control and Sirt1 KO osteoblast was analyzed for the gene expression 
level of various mRNA bone marker proteins via qRT-PCR: KO of Sirt1 in osteoblast 
leads to an increased expression of middle to mature osteoblast marker genes (Alp, 
Opn and Ibsp) compared to WT (B). In contrast, the expression levels of marker genes 
for osteoblast progenitors (A) and mature osteoblast (C) with a Sirt1 KO exhibit no 
significant change compared to WT. 
Since OPN is the most accepted osteoblast middle stage marker, the 
endogenous OPN protein content was determined in Sirt1 KO/WT osteoblast via 
IF staining (depicted in Figure.38.). 
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Figure.38.The osteoblast middle stage marker protein OPN is much more 
abundant in the Sirt1 KO OB cells compared with WT osteoblast cells, IF staining 
for OPN in the organelles of the secretory pathway, e.g. ER, Golgi and secretory 
vesicles is enhanced in Sirt1 KO osteoblast. Bars represent 10 μm. 
It has been published in the literature that specific deletion of SIRT1 in MSC 
leads to decreased in MSC differentiation into osteoblasts and chondrocytes, as 
well as a to reduction in cortical bone thickness and trabecular volume in mice 
(Simic et al., 2013). The above results revealed that the deletion of Sirt1 gene 
actually also promotes the osteoblast differentiation solely in the middle stage of 
compared to the WT. Throughout the entire osteoblast differentiation process it 
can be assumed that SIRT1 actually plays dual roles in distinct differentiation 
stages: promoting differentiation from MSC stage to osteoblast progenitor stage 
and interfering differentiation from pre-osteoblast stage to maturation stage.  
4.3.4. Peroxisome biogenesis and function were significantly attenuated in 
Sirt1 KO osteoblast and in MC3T3-E1 cells with a Sirt1 gene knockdown 
In the literature, it has been shown that SIRT1 may mediate the effect of caloric 
restriction by affecting PPARγ, PGC1-α and FOXOs (Han et al., 2010), which are 
all strongly altered in Pex11β and Pex13 KO osteoblast (described in section 4.1 
and 4.2). Therefore, we also analyzed the gene expression levels coding for 
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protein involved in peroxisome biogenesis and peroxisomal metabolism. To 
analysis this hypothesis, enzyme genes in Sirt1 KO/WT osteoblast were 
determined with qRT-PCR with total osteoblast RNA and IF staining of the tissue 
sections. The results of these experiments are depicted in figures 39-41.  
The results presented in Figure.39. are very similar to the expression levels of 
the examined genes in Pex13 KO osteoblast (Figure.29.). The mRNA expression 
levels for the peroxisome biogenesis genes (Figure.39.A) and the peroxisomal 
metabolic enzymes (Figure.39.C), even the peroxisome membrane transporter 
Abcd1 and Abcd3 (Figure.39.B) were dramatically diminished in Sirt1 KO 
osteoblast compared to WT osteoblast. These results were further confirmed by 
the Sitr1 shRNA knockdown in MC3T3-E1 cells.  
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Figure.39. Knockout of Sirt1 in primary osteoblast and knockdown in MC3T3-E1 
cells induces comparable effects on the mRNA levels for peroxisomal related 
proteins. Sirt1 KO osteoblasts showed decreased expression levels of mRNA for 
peroxisome biogenesis genes (A), peroxisomal transporter (B) and peroxisomal 
metabolic enzymes (C). Sirt1 KO osteoblasts also exhibit strongly decreased Ppar and 
Pgc1. mRNA level (D).Moreover, a knockdown of the Sirt1 mRNA in MC3T3-E1 cell 
leads to comparable effects(E).  
In addition to the observed mRNA alterations, also the number of peroxisome 
and the level of peroxisome protein were decreased (Figure.40.). 
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Figure.40. The abundance of the peroxisome biogenesis proteins PEX13 (A) and 
PEX14(B) are considerably decreased in Sirt1 KO osteoblast compared to WT. 
Indirect IF staining was performed with primary rabbit antibodies against PEX13 and 
PEX14 and donkey anti-rabbit antibodies secondary labelled with Alexa 488 (green). 
Bars represent 10 µm. 
Similar to the biogenesis proteins PEX13 and PEX14, also the protein level for 
catalase (CAT) and the peroxisomal transporter ABCD3. 
 
Figure.41. The abundance of catalase (CAT) and peroxisomal membrane 
transporters ABCD3 are decreased in Sirt1 KO osteoblast compared to WT. 
Indirect IF staining was performed to detect catalase protein (A) and ABCD3 protein (B). 
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As clearly visible catalase and ABCD3 are both decreased in Sirt1 KO osteoblast. Bars 
represent 50 µm.  
In summary, the peroxisome numbers and gene expression peroxisomal 
biogenesis protein as well as catalase and ABCD3 were significantly decreased 
due to a Sirt1 KO in osteoblast. 
4.3.5. Oxidative stress is dramatically increased in primary Sirt1 KO 
osteoblast and in MC3T3-E1 cells with a stable Sirt1 knockdown  
Since the peroxisomal biogenesis and function are strongly attenuated in Sirt1 
KO osteoblast (see Section 4.3.4.), oxidative stress might be present in Sirt1 KO 
cells and cause alterations of osteoblast differentiation. Therefore, some 
experiments were performed to determine a possible increase in oxidative stress. 
H2-DCFDA was used for FACS analysis to detect the total intracellular ROS level 
in Sirt1 KO/WT osteoblast. The higher ROS level suggests that oxidative stress 
(see Figure.42.) is present in Sirt1 KO osteoblast compared to WT osteoblast. 
The reason for the increased oxidative stress might be the lower the antioxidant 
capability in the cells by diminished peroxisomal abundance and functions (see 
Figure.39. and 41.). 
 
Figure.42. Global oxidative stress is increased in MC3T3-E1 cells with a Sirt1 
shRNA knockdown which was determined by H2-DCFDA staining of osteoblast 
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with FACS (A). The ROS level was about 70 % higher in the MC3T3-E1 cells with the 
Sirt1 knockdown compared to WT (B).  
4.3.6. Sirt1 deletion results in an increased bone resorption via alteration of 
the RANKL/OPG system 
The homeostasis of bone remodeling is maintained by the balance of bone 
generation and absorption by osteoblasts and osteoclasts. Interestingly, 
osteoclast differentiation can be regulated by osteoblast through RANKL/OPG 
system. To find out, how the osteoclast differentiation was altered in Sirt1 KO 
mice, the expression levels of Rankl and Opg genes were determined in Sirt1 
KO/WT osteoblasts by qRT-PCR using primary osteoblasts and Sirt1 shRNA 
knockdown in MC3T3-E1 cells (Figure.43.). The reduction of expression level of 
Opg and increase in Rankl in both cell types suggests that the osteoclast 
differentiation could be stimulated by osteoblast regulated RANKL/OPG system 
due to SIRT1 deletion.  
 
 
 
 
Figure.43. The balance of RANKL/OPG system is disturbed in Sirt1 KO osteoblast 
characterized by the significantly reduced expression of Opg and increased 
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expression of Rankl compared to WT osteoblast. Total RNA of A: WT control and 
Sirt1 KO osteoblast and B: Sirt1 shRNA knockdown inMC3T3-E1 cells were analyzed 
for the gene expression level of Rankl and Opg by qRT-PCR. 
4.3.7. Deletion of the Sirt1 gene induces developmental defects, by 
induction of retinoic acid signaling in Sirt1 KO mice 
Our collaboration partner in which I was working for two laboratory rotations 
showed that the retinoic acid binding protein II (CRABPIl) can be deacetylated by 
SIRT1. It is known from the literature that retinoid homeostasis is essential for the 
differentiation process and normal embryonic development. Wherefore, alteration 
in retinoic acid receptors  (RAR) abundance and activity could exert strong 
influences on the differentiation process also on osteoblasts. Retinoid pathway 
activation could have an impact both on the expression of bone marker genes as 
well as on the peroxisome compartment. In line with this, we hypothesized that 
also the nuclear receptor mediating retinoic acid effect might be altered in the 
bone of the Sirt1 KO mice. Therefore, the RAR abundance was analyzed in 
bone of Sirt1 KO/WT mice via IF staining (Figure.44.). The results show that the 
abundance of RAR was strongly increased in the Sirt1 KO bone cells, including 
osteoblast and chondrocyte, associated with the increasing nuclear accumulation 
of CRABPII caused by Sirt1 gene deletion, suggesting that retinoic acid (RA) 
signaling actually has been enhanced in Sirt1 KO bone cells compared to WT.  
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Figure.44. The loss of SIRT1 protein in bone of Sirt1 KO mice increases cellular 
abundance of RAR and OPN in osteoblast compared to WT. Double 
immunofluorescence staining of RARβ and OPN in the diaphysis of bone (femurs).The 
OPN staining (red fluorescence) depicts the differentiated osteoblast (indicated by the 
arrows). The RARβ staining (green fluorescence) displays a much stronger labeling in 
Sirt1 KO tissue, which indicates that the RARβ abundance is higher in Sirt1 KO 
osteoblast compared to WT. Bars represent 10 µm (published as Figure number 7 C in 
Tang et al, 2014). 
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As proven by RARβ staining, this retinoid receptor is strongly induced in the Sirt1 
KO osteoblast. RARβ activation might indeed explain the upregulation of bone 
markers and also of the PPARs and the other “peroxisome-related” gene 
expression (Figure.39.).  
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5. Discussion  
Dysregulation of osteoblasts differentiation and their function has been reported 
in the literature as important factors contributing to a wide range of bone 
diseases, such as osteoporosis in adults or ossification defect and growth 
retardation in children(James, 2013; Marie and Kassem, 2011; Pino et al., 2012; 
Price et al., 1994). According to the report of the World Health Organization 
(Brussels, Belgium, May 2004), the osteoporosis caused more than 8.9 million 
fractures annually worldwide, of which more than 4.5 million occurred in America 
and Europe. Additionally, the dysregulation of RANKL/OPG system which results 
in the over-absorption of bone matrix by differentiated osteoclasts is also the 
main factor contributing to pathogenesis of osteoporosis (McCormick, 2007). 
In this work, the deletion of two of the Peroxin genes, Pex11β and Pex13, caused 
a dysregulation of osteoblast differentiation. These two ZS mouse models with a 
strong metabolic defect were used to investigate how osteoblast differentiation is 
disturbed by peroxisomal dysfunction peroxin. Interestingly, either the 
phenotypes of new born pup skeletons or the progressing of osteoblast 
differentiation were remarkably similar in Pex11β (Qian, 2010a) (Figure.19.-20.) 
or Pex13 KO (Figure.26.-28.) mouse models. In Zellweger patients with 
peroxisome deficiency the growth retardation and craniofacial dysmorphism have 
been noted; however it was not known how these skeleton phenotype was 
induced. Therefore, the Pex11β KO and Pex13 KO mouse model were used here 
to study the molecular pathogenesis of bone defect induced by peroxisomal 
deficiency. Indicated by gene expression level of osteoblast stage markers, the 
osteoblast differentiation process was strongly affected by peroxisomal 
biogenesis and function defect. In primary osteoblasts, the deletion of Pex11β 
and Pex13 genes results in the decrease of SIRT1 (Figure.33.and 34.) and more 
interestingly, the expression level and the protein abundance of the most 
important peroxisome biogenesis genes and metabolic enzymes were 
significantly decreased by KO or knockdown Sirt1 in osteoblast (Figure.39.-41.). 
We have found the deletion of SIRT1 enhances RA signaling (Tang et al., 2014) 
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and the RA has been found negatively regulate the osteoblast mineralization and 
osteoblastogenesis (Bi et al., 2013; Lind et al., 2013). 
5.1. Attenuation of peroxisome biogenesis and peroxisomal functions in 
Zellweger Syndrome and Sirt1 KO mouse model 
5.1.1. The possible role of peroxisomes in osteoblast differentiation 
In the literature there is still no information available on the abundance and 
enzyme composition of peroxisomes in different cell types of the skeleton. 
However, the importance of peroxisomes for the skeleton is well known due to 
abnormal skeletal deformations found in patients with peroxisomal disorders 
(Agamanolis and Novak, 1995; Braverman et al., 2002; Brosius and Gartner, 
2002; Heymans et al., 1985). These observed skeletal defects suggest that 
normal peroxisomal function is essential for endochondral as well as 
intramembranous ossification process.  
Therefore, the present study as well as our preliminary research aimed to find out 
the correlation between peroxisome function and ossification has been carried 
out in our lab. The strong phenotype of ossification defects were shown in ZS 
mice model, such as reduction of bone volume, mass and density, accompanying 
with a delay in the osteoblast differentiation and alteration in bone development 
regulation signaling, such as Wnt signaling(Qian, 2010a). Theoretically, as an 
important metabolic cell organelle, the peroxisome has the potential to influence 
the function of osteoblast. Since peroxisomes are involved in cholesterol and 
ether lipid synthesis, alteration due to peroxisomal problem might influence the 
physiological properties of cell membranes (Brown and London, 1998) and thus 
might facilitate the formation of phospholipid-rich matrix vesicles in hypertrophic 
chondrocytes and osteoblasts. Moreover, the peroxisomes may be involved in 
the synthesis of precursors of vitamin D and retinoids (Fransen et al., 1999) 
which are important for osteoblast maturation. The influence of peroxisomal 
metabolism on osteoblast mineralization also was pointed out by the fact that the 
number of peroxisomes increased during osteoblast differentiation and that the 
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peroxisomes are most abundant in the metabolically activate state, namely in the 
differentiating osteoblast, but less abundant in the stable status, namely in 
osteocyte (Qian, 2010a). 
5.1.2. The Pex13 gene deletion results in the global collapse of biogenesis 
and enzymatic functions 
PEX13 is a metabolic peroxisomal integral membrane protein with an essential 
role in both PTS1 and PTS2 protein import. In the above section “Peroxisome 
Biogenesis” (see section 1.1.2.), it has been mentioned already that in a model of 
Saccharomyces cerevisiae, the cytoplasmic SH3 domain of PEX13 binds to 
PEX5, the PTS1 receptor. Deletion of Pex13 results in a reduction of the level of 
PEX5 associated with the peroxisomal membrane at steady state and loss of 
both PTS1 and PTS2 protein import (Gould et al., 1996). In contrast, peroxisomal 
membrane proteins are still detectable in “ghost” like structures (Santos et al., 
1988) forming spherical membranous structures. However, due to the matrix 
protein import deficiency, peroxisomal metabolic function is seriously disrupted 
within these osteoblast due to Pex13 gene deletion. This has been proven by 
latest data obtained in our lab with Pex13 KO osteoblast stained with 
immunofluorescence assay using primary Pex13 KO osteoblast cells, which 
revealed the import defect of peroxisomal matrix protein, such as the antioxidant 
enzyme Catalase was mislocalized to the cytoplasm and the nucleus of 
osteoblasts. Moreover, in IF staining for PEX14, peroxisomal membrane “ghosts” 
are present, which are however less intensive by stained for the peroxisomal lipid 
transporter ABCD3. 
In primary Pex13 KO osteoblast, the gene expression levels of peroxisome 
biogenesis and peroxisomal enzymes were severely down-regulated (Figure.29.), 
possibly explaining the lower staining intensities for other peroxisomal matrix 
enzymes and membrane protein than catalase and ABCD3. 
In comparison to Pex11β KO mice, in Pex13 KO osteoblast the defects in the 
peroxisomal protein import and metabolic abnormalities have been found, exactly 
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like in ZS patients and ZS mouse models of Pex2 and Pex5 KO (Baes et al., 
1997; Faust et al., 2001), which result in the accumulation of VLCFA in the liver, 
brain, and skin fibroblasts and severe reduction of the oxidation of branched-
chain fatty acid in fibroblasts (Maxwell et al., 2003).  
5.1.3. The peroxisomal biogenesis and peroxisomal metabolic function are 
diminished in Sirt1 KO osteoblast cells 
The obtained results in this thesis (Figure.39.-41.) indicate that also the deletion 
of the Sirt1 gene diminishes peroxisomal biogenesis and peroxisomal metabolic 
functions. The expression levels of many peroxisomal biogenesis genes such as 
Pex5, Pex11α, Pex11β, Pex11γ, Pex13, Pex14, Pex19, peroxisomal antioxidant 
(catalase), and β-oxidation enzymes (Acox1-3, Mfp1,2), were decreased. 
Similarly a decreased number of peroxisomes as well as decreased protein of 
PEX13 and PEX14 levels were noted in Sirt1 deficient osteoblasts (Figure.40.) 
and for the peroxisomal targeting sequence 1-containing proteins (data not 
shown) which were all reduced in individual peroxisomes of Sirt1 KO osteoblast.  
Peroxisome biogenesis and metabolism are under the control of intrinsic 
transcriptional pathways including the PPAR nuclear receptors and their co-
activator PGC-1. Previous studies have shown that SIRT1 modulates the 
activities of both PPARs and PGC-1, either through direct deacetylation or via 
co-factor recruitment in response to different environmental cues (Li, 2013). To 
further dissect the molecular mechanism of peroxisome biogenesis deficiency in 
Sirt1 KO osteoblasts, we examined the mRNA levels of PPAR, the predominate 
form of PPARs in this cell type, and PGC-1. Most interestingly, the expression 
levels of the Ppar and its co-activator Pgc-1 were significantly decreased (see 
Figure.39.D). It has been known that the “switch” of adipogenesis or 
osteogenesis of MSC are regulated by the master regulator PPARγ via 
ROS/FoxO/PPARγ/β-catenin cascade under oxidative stress and lipid toxicity 
condition in osteoblast (Section 1.3.2.2.). These results suggest that the down-
regulated Ppar and co-factor Pgc-1 may contribute to the earlier differentiation 
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of Sirt1 KO osteoblast under the increasing oxidative stress (Figure.42.). These 
observations, together with our previous data on peroxisomal deficient animals 
indicate that peroxisomal dysfunction in Sirt1 KO mice might contribute to the 
alteration of osteoblast functions and ossification disturbance of these animals.  
Furthermore, the latest literature suggested the PPARβ also might be the key 
regulator of bone turnover and the crosstalk between osteoblasts and osteoclasts. 
The osteoblast differentiation can be promoted by amplified Wnt-dependent and 
β-catenin-dependent signaling due to activation of PPARβ, in particular the 
activated PPARβ can increasing binding activity to PPRE where is also located 
within the promoter region of Wnt signaling co-activator LRP5 to promote its 
expression level (Scholtysek et al., 2013). Moreover, it has been found that the 
PPARα expression level was up regulated during the osteoblast differentiation 
process (Qian, 2010a). Therefore, the dysregulation of Sirt1 KO osteoblasts also 
might be caused by a possible alteration of PPARβ and α and which might be 
studied in further experiments. 
5.2. Skeletal ossification defect and osteoblast dysregulation of 
differentiation 
5.2.1. Severe ossification defect and the skeletal deformation of Zellweger 
Syndrome and Sirt1 KO mouse model 
5.2.1.1. Strong phenotype of Zellweger Syndrome and ossification defect in 
Pex11β KO mice 
The recognition of the Pex11β KO mouse as a ZS model was based on the fact 
that several pathological features were shared by Pex11β KO and Pex5 (Baes et 
al., 1997; Baumgart et al., 2001) or Pex2 (Faust and Hatten, 1997; Kovacs et al., 
2004) mouse models, which reproduce virtually all of the hallmarks of the human 
disease, including neuronal migration defects, enhanced neuronal apoptosis 
within the neocortex, intrauterine growth defects retardation which cause a 
developmental delay, hypotonia, and neonatal lethality (Li et al., 2002b). 
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Even though the typical craniofacial dysmorphism of the ZS patient is not 
observed in these mouse models, a calvariae ossification delay was described 
(Faust and Hatten, 1997). The human disease RCPD is autosomal recessive 
disorder caused by the defects in PEX7 encoding the receptor for PTS2-targeted 
peroxisome matrix enzymes (Braverman et al., 1997; Steinberg et al., 2006). 
This disease is chartered be the strong phenotypes of skeletal, eye and brain 
abnormalities and the animal model of Pex7 KO mice shows defect in ossification 
of distal bone elements of the limbs as well as parts of the skull and vertebrae, 
and abnormalities in lens fibers(Braverman et al., 2010; Brites et al., 2003). 
5.2.1.2. The Pex13 KO mice show growth and developmental abnormalities 
of Zellweger Syndrome but delayed ossification defect started later after 
birth compared to Pex11β KO mice 
Previous quantitative morphometric analysis via fpvCT determination has been 
done in our laboratory on E19 Pex13 KO mice  revealed no significant 
differences in bone volume and bone mass between Pex13 KO mouse pups and 
WT (my preliminary experiments data not shown); In contrast, in E19 Pex11β KO 
pups, a decrease of total bone volume, bone mass and whole-body bone mineral 
density has been observed compared to WT (Qian, 2010a). 
The lifespan of Pex13 KO pups was around 6-12 hours after birth which is 
slightly longer than that of Pex11β KO mouse pups that die meanwhile before 
birth. Therefore, to determine the possible ossification defect of Pex13 KO 
mouse pups, the P0.5 Pex13 KO/WT mouse pups were used for fpvCT 
determination and quantitative morphometric analysis. The results revealed that 
the bone volume of Pex13 KO mouse pups was around 80% of that of littermates 
WT and HTZ pups at the same stage, suggesting a severe ossification defect 
due to Pex13 gene deletion (Figure.26.). We observed , the severe skeletal 
deformation of Pex13 KO mouse pups, in particular the reduced size of the skull 
and the long bones such as tibia and femur (Figure.26.), which might be the 
reason for the maintenance of a contracted “C” posture that appeared to 
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particularly affect the hind limbs in the newborn Pex13 KO mouse pups 
(Figure.10.) (Maxwell et al., 2003). 
5.2.1.3. Intrauterine growth retardation and developmental defects of Sirt1 
KO mouse pups 
It has been believed that SIRT1 plays a critical role in development, which can be 
proven by deletion of the Sirt1 gene which results in severe developmental 
defects, such as neonatal lethality, defective germ cell differentiation, 
developmental defects of the retina and heart and intrauterine growth retardation 
(Cheng et al., 2003; McBurney et al., 2003; Wang et al., 2008). For instance, only 
around 1% of Sirt1 KO mice with a 129SvEv/FVB background can survive (Wang 
et al., 2008). By using a general Sirt1 KO mouse in the C57BL/6 background we 
have found that the mineralization process of endochondral ossification was 
delayed in Sirt1 KO mice compared to WT littermates (Tang et al., 2014).  
Additionally, even the molecular mechanism of the regulation of development 
and stem cells by SIRT1 are still not completely understood, the wide spread 
developmental defects of Sirt1 KO mouse pups might be due to the 
multifunctionality and central role of the SIRT1 protein in regulation of the activity 
of a range of important transcription factors and transport proteins (Tang et al., 
2014). It has been determined that SIRT1 also regulates skeletal myoblast 
differentiation (Fulco et al., 2008; Fulco et al., 2003),it influences 
spermatogenesis (Coussens et al., 2008) and modulates of neural and glial 
specification from neural precursors cells (Kang et al., 2009; Prozorovski et al., 
2008). 
In summary, either the Zellweger Syndrome or the Sirt1 KO mouse model all 
showed the typical ossification defect and abnormal bone development, which 
can be summarized and compared as following Table.17. 
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Table.17. The comparison of ossification defect of Zellweger Syndrome and the 
Sirt1 KO mouse model 
Ossification defect 
Zellweger Syndrome Mice model  
Sirt1 KO Mice Pex11β KO  
mice pups  
Pex13 KO  
mice pups 
Time point of ossification 
defect can be observed  
E18.5 P0.5  
No obvious aeration 
observed till P0.5  
How the ossification was 
impaired compared with 
WT control mouse. 
Dramatically 
decreased bone 
mass, especially in 
calvaria, vertebrae 
and limbs (Qian, 
2010a) 
Small skull, 
shorter size of 
long bones eg. 
tibiae, ribs, 
femora  
The mineralization 
very lightly 
decreased (Tang et 
al., 2011) 
The comparison in Table.17. reveals the Zellweger Syndrome mice, the Pex11β 
KO and Pex13 KO mice pups, have much stronger ossification defect phenotype 
than Sirt1 KO mice pups, therefore the attenuation of SIRT1 in Pex11β KO and 
Pex13 KO osteoblast (Figure.33. and 34.) maybe not the dominant factors results 
in the ossification delay in Zellweger Syndrome mice. Additionally, since the 
ossification defect can be observed earlier in Pex11β KO mice compared with 
Pex13 KO mice, the Pex11β KO osteoblast functions might be more disturbed 
than the one of Pex13 KO osteoblast. 
5.2.2. Interference of the osteoblast differentiation process in a different 
manner within Zellweger Syndrome and Sirt1 KO mouse models  
It has afore been described (see Section 1.3.2.1.) that the differentiation of pre-
osteoblasts into mature osteoblasts and osteocytes is a multi-stage process 
which involves coordinated induction of various markers (Table.3.). The 
differentiation of osteoblast is a critical requisite for ossification and bone 
production. 
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5.2.2.1. The role of osteoblast differentiation in ossification  
Ossification can be classified as the intramembranous ossification and the 
endochondral ossification (Caetano-Lopes et al., 2007). Compared to the 
endochondral ossification, the intramembranous ossification is occurring without 
any participation of intermedia structure. The formations of the flat bones of the 
calvaria, the clavicle, some parts of the mandible, parts of facial bones and the 
cranial suture lines, are generated directly from the osteoblasts which 
differentiates from MSC.  
Endochondral ossification is also called secondary ossification process and it is 
the essential ossification process for the long bone growth process. In contrast to 
intramembranous ossification, cartilage plays an essential role during 
endochondral ossification. Firstly, the chondrocytes which differentiate from 
MSCs form a cartilaginous model of the bone by their extracellular matrix. 
Secondly, proliferating cartilage will develop a hypertrophic cartilage. Thirdly, the 
apoptosis of hypertrophic chondrocytes and opening by chondroclast enable the 
invasion of blood vessels to transport the MSCs to the cavities which settle down 
on mineralized cartilage surface and finally differentiate into mature osteoblasts 
which deposit bone matrix (Brighton et al., 1973; Caplan, 1988). 
Since the primary mineralization process of ossification is carried out by maturely 
differentiated osteoblast, the osteoblast differentiation is a critical step to 
determine the ossification process. The reason for the alteration of the osteoblast 
differentiation (Figure.19.,20.,28.and 37.) might be caused by the peroxisome 
biogenesis and functions as found in Pex11β, Pex13 and Sirt1 gene deleted mice 
(Figure.17.,18., 29. and 39.), and also contribute to the difference among defects 
in the ossification caused in these mice models.  
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5.2.2.2. Osteoblast differentiation was delayed in Zellweger Syndrome and 
promoted in Sirt1 KO mice model 
Primary osteoblasts were isolated from the neonatal mouse calvaria which is 
formed through the intramembranous ossification process. In the cell culture 
model it was described that, the MSCs directly condense and differentiate to 
osteoblast progenitors and further differentiate into pre-osteoblast and then into 
mature functional osteoblast for mineralization. Therefore the initial cell culture 
isolated from mouse calvaria contain a mixture of osteoblast progenitor cells 
which forward to differentiate to pre-osteoblast, differentiating pre-osteoblast and 
differentiated mature functional osteoblast (See Section 1.3.). Previous 
experiments in our lab have found that the middle stage osteoblast marker OPN 
and osteoblast maturation stage marker BGLAP were continuously increased 
throughout a 10 day period of osteoblast culturing (Qian, 2010a) which indicates 
a combination of osteoblast in different stages which were progressing in 
differentiation toward the mature stage. Therefore, the different portions of 
osteoblast in different stages could be screened by the expression level of 
osteoblast differentiation stage markers. 
According to the expression level of osteoblast stage markers in Pex11β and 
Pex13 KO osteoblast, the differentiation process is partially delayed in Pex11β 
KO osteoblasts (Figure.19.and 20.), whereas the osteoblast differentiation 
process is delayed in all stages of Pex13 KO osteoblast differentiation 
(Figure.28.), wherefore the bone mineralization defect occurred in these ZS 
animal models (Figure.27.) (Qian, 2010a). Interestingly, even the osteoblast 
differentiation process is less delayed in Pex11β KO mice than Pex13 KO mice; 
the ossification defect in Pex11β KO mice is more severe than in Pex13 KO mice, 
as for the fact that the ossification defect of Pex11β KO mice was detected at 
E19 but only after day of P0.5 in Pex13 KO mice. 
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In summary, the alteration of differentiation of osteoblasts isolated from 
Zellweger Syndrome mice and the Sirt1 KO mouse can be summarized and 
compared as following Table.18. 
Table.18.The comparison of osteoblast differentiation progress Zellweger 
Syndrome and the Sirt1 KO mouse model 
Osteoblast 
Differentiation Process 
Early Stage  Middle Stage Mature Stage 
Osteoblasts 
isolated from 
Zellweger 
Syndrome Mice  
Pex11β 
KO  
Slightly increased Delayed  Severely delayed  
Pex13 
KO 
Severely delayed Severely delayed Severely delayed 
Sirt1 KO osteoblast 
No significant 
alteration 
Strongly 
increased 
expression of 
bone markers  
No significant 
alteration 
Similar like the ossification phenotype (Table.17.), the differentiation process 
might be different in Pex11β KO and Pex13 KO compared with Sirt1 KO 
osteoblast as indicated by expression level of bone markers. However, in the 
Sirt1 KO osteoblast, the hyperexpression of middle stage osteoblast Opn and 
Ibsp (Figure.37.) might be result in the negative consequence to embryonic 
development of Sirt1 KO mice. It has been known the OPN is a potent 
constraining factor on haemopoietic stem cells proliferation and overexpression 
of Opn is a feature of haemopoietic malignancies, such as multiple myeloma and 
chronic myeloid leukaemia (Haylock and Nilsson, 2006). In human body, the 
Bone sialoprotein is expressed in breast, lung, thyroid and prostate cancers and 
expression of bone sialoprotein by cancer cells could play a major role in the 
mineral deposition and in preferred bone homing of breast cancer cells (Ogata, 
2008). 
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5.3. Signaling pathways of osteoblast differentiation regulation are already 
altered in Pex11β, Pex13 and Sirt1 KO mouse models 
Critical roles of peroxisomes in the development of calcified tissues has been 
noted in previous researches in our lab, such as the peroxisome abundance 
increasing during differentiation of ameloblasts and odontoblasts and strong 
heterogeneity of peroxisomal enzyme content during differentiation of these 
dental cell types (Stelzig et al., 2013)  
It has been discussed in a previous section (see Section 1.3.2.2.) that the 
precursors of various cell types of calcified tissue, such as osteoblasts, and 
osteocytes are differentiated from MSCs; whereas the MSCs can also 
differentiate to adipocytes. This “switch” of inverse relationship balancing 
between osteogenic and adipogenic lineage orientation is controlled by several 
signaling pathways which converge on various transcription factors, such as 
FoxO1, PPARγ and Runx2 (James, 2013; Teixeira et al., 2010). These key 
transcription factors can be realized as the master regulators of adipogenesis 
and osteogenesis by determining and sensing environmental alterations, which 
might be altered by the peroxisomal dysfunction due to oxidative stress and lipid 
toxicity. 
5.3.1. Strong oxidative stress in Pex11β, Pex13 and Sirt1 KO osteoblast 
Previous research has revealed that missing peroxisome proliferation capacity 
caused by Pex11β gene deletion resulted in strongly increased oxidative stress 
and lipid peroxidation, determined by the increase of lipid peroxidation product 4-
hydroxynonenal (4-HNE) (Qian, 2010a). In my research, the TUNEL assay was 
used to detect apoptosis in Pex11β KO osteoblast cell culture: that might be 
caused by the possible severe oxidative stress; the results showed that the 
number of cells positively stained with the TUNEL assay was significantly higher 
in KO than in WT osteoblast culture (Figure.24.). Moreover, the TUNEL-positively 
stained osteoblasts showed also the typical alterations of nuclear morphology 
(shrinking, condensation, and fragmentation of chromatin) that are observed 
during apoptosis. It is universally accepted that the TUNEL staining cannot only 
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detect the apoptotic cells in situ, but also DNA damage associated with non-
apoptotic events caused by exposure to toxic compounds or other stress (Ansari 
et al., 1993). Indeed, it has been found that oxidative stress induced DNA 
damage was also dramatically increased in osteoblast of Pex11β KO mouse 
calveria as shown by strong nuclear IF labelling with an antibody against 8-
hydroxy-2’-deoxyguanosine (8-OHdG) (Qian, 2010a). Therefore, the osteoblast 
apoptosis may be induced by oxidative DNA damage in Pex11β KO osteoblast. 
Also in Pex13 KO animal a strong oxidative response was stimulated by the 
oxidative stress in the bone (Figure.30.) and in osteoblasts culture (Figure.31.). 
Maybe one of the reasons why catalase is not degraded in the cytoplasm and 
even transported to the nucleus is to prevent osteoblasts against cell death. 
Catalase is one of the fastest enzymes to degrade H2O2 and has a very high 
capacity to remove this reactive oxygen species. Cytoplasmic and nuclear 
catalase is a typical feature of peroxisomal matrix protein import deficiencies, 
whereas most other peroxisomal enzymes are degraded in the cytoplasm. 
Interestingly, reduction of peroxisomal enzymes and transporters and biogenesis 
proteins were also present in the Sirt1 KO osteoblast, and the ROS levels 
significantly increased in MC3T3-E1 cells with a Sirt1 shRNA knockdown 
(Figure.42.). 
5.3.2. Runx2 functional activity was attenuated in Pex11β and Pex13 
osteoblast cells  
Runx2 is a member of the Runx family of transcription factors and the importance 
of this transcription factor for human and animal physiology can be determined 
by the human disease cleidocranial dysplasia due to Runx2 gene deficiency 
(Mundlos et al., 1997; Otto et al., 1997; Ziros et al., 2008). This transcription 
factor is also essential for normal osteoblast differentiation, maturation and 
homeostasis (Ziros et al., 2008).The study on the functions of Runx2 started from 
the capability of RUNX2 to induce the differentiation of multipotent MCS into 
immature osteoblasts and guiding the immature bone formation (O'Donnell and 
Meyers, 1985). In particular the overexpression of Runx2 in MSC cell lines leads 
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to an up-regulation of osteoblast specific genes (Ducy et al., 1997). Interestingly, 
in later research it has been found that, RUNX2 actually plays “dual-roles” in the 
different stages of the osteoblast differentiation process. It enhances osteoblast 
differentiation at an early stage when it has a high level of expression and inhibits 
osteoblast differentiation at a late stage when its expression level is down 
regulated (Komori, 2003). Therefore, the entire osteoblast differentiation process 
consist of two periods: differentiation from MSCs to precursor osteoblasts is 
regulated by RUNX2 and from Runx2-expressing precursors into mature and 
functional osteoblasts is regulated by Osterix (Sinha and Zhou, 2013).  
Being an essential transcription factor for osteoblast differentiation, the DNA 
binding capability is critical for the proper function of RUNX2. Interestingly, the 
Runx2 gene expression and functions can be partially autoregulated by binding 
its own promoter during bone formation (Drissi et al., 2000). In Pex11β and 
Pex13 KO osteoblast, both the gene expression of Runx2 and Osterix were 
strongly down regulated (Figure.19.and 28.), whereas there was no change in 
Sirt1 KO osteoblast compared to WT (Figure.37.). This reveals that the activation 
of bone-specific genes were severely repressed in ZS mice compared to Sirt1 
KO mice. 
The results from the luciferase transcriptional assay with plasmids containing 
RUNX2 DNA binding sequences show the dramatically down-regulated RUNX2 
DNA binding capability in Pex11β shRNA knockdown MC3T3-E1 cells 
(Figure.23.) and primary Pex13 KO osteoblasts (Figure.32.) compared to WT. It 
has been known that RUNX2 regulates Osterix expression at an early stage of 
osteoblast differentiation and Osterix is required for the major signaling pathways 
fibroblast growth factor (FGF), Wnt, and Indian hedgehog (IHH) signaling 
pathways during skeletal development (Komori, 2011). The latest research found 
the RUNX2 DNA binding can be repressed by oxidative stress (ROS) and 
compensated by antioxidants in endothelial cells to regulate the further 
differentiation process of these cells (Mochin et al., 2014). Therefore, it can be 
assumed the decreased RUNX2 DNA binding capability may be caused by the 
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increasing oxidative stress due to peroxisomal dysfunction in Pex11β shRNA 
knockdown MC3T3-E1 cells and Pex13 KO osteoblasts. 
In addition to its role in osteoblast differentiation, RUNX2 seems to control the 
cell cycle. Indeed, the severe reduction of the gene expression and protein 
abundance of RUNX2 (Qian, 2010a) may contribute to the remarkable alteration 
of the cell cycle of Pex11β KO osteoblast compared to WT (Figure.25.). It has 
been reported that RUNX2 can play ambivalent roles in tumorigenesis, in 
particular it initiates the proliferative phase of cell differentiation in an oncogenic 
manner, whereas it promotes the arrest of the cells into the post-mitotic state 
anti-oncogenically (Thomas and Kansara, 2006). It has been found that in 
osteosarcoma the DNA copies and expression of RUNX2 were strongly up-
regulated. Therefore RUNX2 may have both tumor suppressive and tumor 
promoting roles in bone morphogenesis (Martin et al., 2011).  
5.3.3. The function of PPAR, PPRE DNA binding activity, was increased in 
Pex11β KO osteoblast 
PPARs act as metabolic sensors and central regulators of fat and glucose 
homeostasis (Ammerschlaeger et al., 2004; Duclos et al., 1997; Goll et al., 1999; 
Osumi et al., 1990). PPARs of all subtypes form heterodimers with RXRs and 
bind to consensus peroxisome proliferator response elements (PPRE), 
composed of two core motifs separated by a single base pair (DR1 element: 5’-
AGGTCA-N-AGGTCA-3’) (Michalik et al., 2006). PPRE-driven luciferase gene 
report gene assay is an efficient tool for the evaluation of potential PPAR 
agonists (Tsai et al., 2014). Indeed also in this study an increase of PPRE activity 
in Pex11β KO osteoblast (Figure.22.) was noted possibly caused by increased 
oxidative stress and the accumulation of oxidized fatty acid as ligands for PPARγ 
activity. Interestingly, PPARγ is a major catabolic regulator of bone mass in mice 
and humans. It has been shown that stimulation of PPARγ inhibits osteoblast 
maturation and can transdifferentiate mature osteoblasts into adipocytes (Lecka-
Czernik et al., 2002; Nuttall et al., 1998). Indeed, in Pex11β or Pex13 KO animals 
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inhibition of osteoblast maturation and a reduced bone mass were found. Under 
normal conditions in WT cells, PPARγ is suppressed during osteoblastogenesis 
(Kang et al., 2007) and the PPARγ knockdown enhances osteogenesis (Akune et 
al., 2004; Yamashita et al., 2006). In contrast an increase in PPARγ is 
accompanied by a decrease in canonical wnt signaling and the translocation of 
RUNX2 into the cytoplasm, leading to less osteoblast differentiation and 
decreased ossification (Tanaka et al., 2012). This knowledge from the literature 
fully supports the results of this thesis that peroxisome deficiency leads to 
PPARγ overactivation and in consequence to the observed ossification defect in 
our Pex11β or Pex13 KO animal model. 
5.3.4. The FoxOs protect osteoblast against oxidative stress with 
transcriptional function 
The FOXO forkhead transcription factors are involved in metabolism control, cell 
survival, cellular proliferation, DNA damage repair response, and stress 
resistance. Their transcriptional activity is regulated through a number of 
posttranslational modifications, including phosphorylation, acetylation and 
ubiquitination (Kousteni, 2011b; Obsil and Obsilova, 2011). In principle, the 
protein stability and transcriptional activity of FoxOs can be activated by oxidative 
stress, and this will initiate an anti-oxidative defense response. Thus, FoxOs 
transcription factors can protect osteoblasts against oxidative stress to maintain 
the bone mass homeostasis by activating genes regulating ROS scavenge and 
apoptosis (Ambrogini et al., 2010). The increased apoptosis (Figure.24.) and 
strong alteration of cell cycle (Figure.25.) in Pex11β KO osteoblast may be 
contributed by down-regulated transcriptional activity of FoxOs, indicated by the 
decrease of FoxOs DNA binding capability (Figure.21.) due to Pex11β gene 
deletion. 
Beside the DNA binding, also nuclear translocation is essential for the 
transcriptional function of FoxOs, which are both regulated by a two-tiered 
mechanism of deacetylation and phosphorylation (Kousteni, 2011b). It has been 
found that FoxOs can be acetylated by p300 and nuclear hormone receptor 
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coactivators CREB-binding protein (CBP) (acetyltransferase) under conditions of 
cellular stress and also can be deacetylated by expression of sirtuins in the 
nucleus (Sandri et al., 2004). 
Especially the most important functional member of the FoxO family, FoxO1 can 
not only maintain bone homeostasis with promoting osteoblast proliferation by 
regulating protein synthesis and maintain redox balance (Rached et al., 2010), 
but also regulates glucose metabolism via the skeleton with transcriptional 
function in osteoblast when the skeleton functions as an endocrine organ 
(Kousteni, 2011a). Significantly increased levels of ROS and lipid peroxidation 
products as well as an activation of the stress-evoked p53-dependent signaling 
cascade have been found in the bones of FoxO1 KO mice. On this basis, the 
FoxO1 function can be identified as a crucial regulator of osteoblast physiology 
and it provides a direct mechanistic link between oxidative stress in osteoblast 
and control of bone mass (Ambrogini et al., 2010; Rached et al., 2010). The 
ossification defects in Pex11β KO mouse are partially caused by the reduction of 
the FoxO1 protein (Qian, 2010a) and the decreased FoxO DNA binding 
capability due to oxidative stress in Pex11β KO osteoblasts. 
5.4. The regulation of SIRT1 on osteoblast and osteoclast differentiation  
5.4.1. The transcriptional functions of PPARγ and FoxOs and RUNX2 are 
related with SIRT1 interaction and deacetylation 
It has been found that many important transcription factors, in particular PPARs 
(α and γ), PGC-1α and FoxOs interact and be deacetylated by SIRT1 to promote 
metabolic responses to cellular stimulation, such as oxidative stress and fatty 
acid oxidation(Haigis and Sinclair, 2010). Further, PPARγ can directly interact 
with SIRT1 and its DNA binding and transcriptional function are in part related to 
SIRT1 deacetylation activity (Han et al., 2010). The latest literature suggests that 
the Sirt1/Runx2 association and deacetylation of Runx2 may partially influence 
the transcriptional function of RUNX2 and contribute to the regulation of 
differentiation of MSCs and pre-osteoblast to osteoblasts (Shakibaei et al., 2012). 
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Most importantly, the SIRT1 protein is contradictorily translocated into the 
nuclear region in Pex11β and Pex13 KO osteoblast. In particular the nuclear 
abundance of SIRT1 was massively reduced in Pex11 KO osteoblast (Figure.33.). 
In contrast it was very concentrated in Pex13 KO osteoblast compared to WT. 
However, this difference suggests that SIRT1 functions were severely altered in 
Pex11β and Pex13 KO osteoblast; we cannot conclude a different outcome in 
Pex11β and Pex13 KO osteoblast, because SIRT1 actually regulates the 
transcriptional capability of PPARs, FoxOs and Runx2 via deacetylation. Further 
investigations on how PPARs, FoxOs and RUNX2 are regulated by SIRT1 with 
the deacetylation of these transcription factors should be performed in Pex11β 
and Pex13 KO osteoblast. 
5.4.2. The Regulation of retinoic acid signaling by SIRT1 deacetylation 
It has been known that the retinoid homeostasis is critical for normal embryonic 
development; in particular both the deficiency and excess of these compounds 
are associated with congenital malformations (Tang et al., 2014). The retinoic 
acid binding protein II (CRABPII) can act as a retinoic acid (RA) carrier which can 
transport RA from the cytosol into the nucleus upon RA binding to activate the 
nuclear RA receptors (Delva et al., 1999; Dong et al., 1999; Sessler and Noy, 
2005). Moreover it has been determined that the cellular CRABPII can be 
deacetylased by SIRT1 and that the loss of SIRT1 increases the nuclear 
accumulation of CRABPII (Tang et al., 2014).  
As a key regulatory factor, Sirt1 mediates the pleiotropic effects of RA and 
therefore the RA binding to retinoic acid receptors  (RAR) can be altered by a 
Sirt1 gene deletion which in turn could induce a nuclear accumulation of 
CRABPII. 
5.4.3. The osteoclast differentiation can be encouraged by osteoblast cell 
SIRT1 protein deletion via the RANKL /OPG system 
Previous studies have shown that in response to bone-resorbing factors, 
osteoblasts release RANKL to bind RANK on the surface of osteoclasts, 
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promoting the differentiation of osteoclasts through activation of NFATc1, a 
master regulator of osteoclastogenesis (Khosla, 2001; Nakashima and 
Takayanagi, 2011). Osteoblasts also produce OPG, a soluble decoy receptor of 
RANKL, for the competition of RANKL with RANK, and thereby limiting osteoclast 
formation.  
Indeed, a significant interference with this system was noted in Sirt1 KO cells, 
exhibiting higher Rankl and lower Opg mRNA levels compared to WT cells. This 
suggests that RANKL can promote osteoclast precursor cells to further 
differentiate to functional osteoclasts, whereas OPG can bind to RANKL to 
diminish this promoting effect. Therefore, the ratio of intercellular RANKL/OPG 
secreted by Sirt1 KO osteoblast may also increase, which may possibly result in 
an increase of osteoclasts differentiation promoting effects in Sirt1 KO mice 
compared to WT. For further confirmation, an ELISA test should be applied to 
detect intercellular soluble RANKL/OPG protein concentration in Sirt1 KO/WT 
mice. 
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6. Summary 
Peroxisomes are cell organelles that play critical roles from yeasts to humans 
during development, differentiation and morphogenesis and host a wide range of 
essential metabolic pathways such as lipid metabolism and the free radical 
detoxification. The importance of normal peroxisomal function and signaling in 
bone development is demonstrated by patients with Zellweger syndrome (ZS) 
and ZS mouse models. Zellweger syndrome is a human disorder caused by 
mutations in peroxisomal biogenesis genes. Patients exhibit typical skeletal 
deformations in addition to other developmental defects. Similarly, SIRT1, a 
highly conserved NAD+-dependent protein deacetylase, regulates lipid and 
antioxidative metabolism as well as proliferation pathways to extend mammalian 
lifespan, through deacetylation of histones and central transcription factors and 
cofactors, such as PPARs, FoxOs and RUNX2.  
By using the Pex11 and Pex13 KO animal models with a Zellweger phenotype 
including strong ossification defects and skeletal deformation, we found that the 
differentiation and maturation processes in primary osteoblasts isolated from 
these animals were dramatically delayed when peroxisome biogenesis and 
peroxisomal enzymatic function were dysfunctional. Furthermore in osteoblasts 
of these ZS mouse osteoblasts, cell apoptosis and cell cycle were severely 
altered as well as the DNA binding capability of PPARs, FoxOs and RUNX2 
together with increasing cellular oxidative stress and lipid toxicity.  
Interestingly, disturbances within the process of ossification and osteoblast 
differentiation were observed also in the Sirt1 KO mouse model. Moreover, the 
peroxisome biogenesis and their enzymatic functions were significantly reduced 
and oxidative stress was increased. Interestingly we could show that SIRT1 also 
maintains homeostatic RA signaling by regulating the subcellular localization of 
CRABPII through its deacetylation activity. Therefore, the nuclear accumulation 
of the hyper-acetylated CRABPII and elevated RA signaling were induced by 
SIRT1 deficiency, which resulted in the accelerating differentiation of 
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mesenchymal stem cells (MSCs) and developmental defects in Sirt1 KO mice. 
Whether the deacetylation function of SIRT1 may have been altered in Pex11 
and Pex13 KO osteoblast due to the strong downregulation of the SIRT1 
abundance and nuclear translocation has to be investigated in future. Additionally, 
the capability to enhance osteoclastogenesis was increased in Sirt1 KO 
osteoblast via an unbalanced RANKL/OPG system. 
Taken my results together and in respect to our previous data and the latest 
literature, the functions of peroxisomes in these cell types are summarized in 
Figure.45. The peroxisome contributes to the maintenance of the homeostasis of 
lipid metabolism and cellular redox stress. Peroxin gene deletion induced 
peroxisomal dysfunction which results in increased cellular oxidative stress, lipid 
toxicity and possible alterations in the deacetylation state of SIRT1. The activity 
of the transcription factors PPARs, FoxOs and RUNX2 induced by oxidative 
stress and lipid accumulation might be altered by SIRT1 deacetylation, as well as 
the RA signaling and this interference may in part contribute to the severe 
changes of differentiation, cell cycle, apoptosis and proliferation process 
observed in osteoblast and ossification disturbance of ZS mice.  
 
Figure.45. Schematic illustration of the possible mechanism of peroxisome 
regulation on osteoblast differentiation via the SIRT1 deacetylation activity. Ox: 
oxidative stress; AC: acetylation.   
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7. Zusammenfassung 
Peroxisomen sind Zellorganellen, die von Hefen bis hin zum Menschen an einem 
breiten Spektrum wichtiger  Stoffwechselwege beteiligt sind. Außerdem spielen 
sie eine wichtige Rolle im Lipidaufbau,  beim Abbau freier Radikale, sowie in der 
Entwicklung, Differenzierung und Morphogenese. Das Zellweger Syndrom (ZS) 
sowie ZS-Mausmodelle belegen die Wichtigkeit einer normalen peroxisomalen 
Funktion  während der Knochenentwicklung. Diese humane Erkrankung ist durch 
Mutationen von Peroxin-Genen mit Verlust der peroxisomalen Funktion 
verursacht, und ist durch typische Skelettfehlbildungen und weitere 
Entwicklungsdefekte gekennzeichnet. Die hochkonservierte, NAD+-abhängige 
Proteindeacetylase SIRT1 reguliert den Lipidaufbau, den antioxidativen 
Stoffwechsel, sowie die Proliferation. SIRT1 ist einerseits an der Verlängerung 
der Lebensdauer von Säugern beteiligt und beeinflusst andererseits 
Erkrankungen, die mit dem Stoffwechsel und dem Altern zusammenhängen. Die 
Funktionsweise von SIRT1 beruht auf der Deacetylierung von Histonen und 
Transkriptionsfaktoren und deren Co-Faktoren wie z.B. PPARs, FoxOs und 
RUNX2. 
Mit Hilfe von Pex11- bzw. Pex13-KO-Mäusen (ZS-Mausmodelle), die ZS-
typische Phänotypen aufweisen, stellten wir fest, dass die Differenzierung und 
Reifung von primären Osteoblasten (OB) aus diesen ZS-Mäusen stark verzögert 
waren, sobald die Peroxisomentwicklung und die enzymatischen Funktionen 
zusammenbrachen. Ferner hält SIRT1 die RA-Homöostase mittels der 
Acetylierungs-Aktivität, die für die Regulierung der subzellulären Lokalisierung 
von CRABPII verantwortlich ist, aufrecht. Eine SIRT1-Defizienz induzierte die 
nukleäre Akkumulation des hyperacetylierten CRABPII und erhöhte die RA-
Signalkaskade. Dies bewirkte eine beschleunigte Differenzierung der 
mesenchymalen Stammzellen (MSC) und führte zu Entwicklungsstörungen in 
Sirt1-KO-Mäusen. Ob die in Pex11- und Pex13-KO-OB gefundene verminderte 
SIRT1-Expression und SIRT1-Translokation in den Nucleus tatsächlich zu einer 
Redukion der Deacetlyierung von SIRT1-Substraten führt, müssen zukünftige 
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Experimente zeigen. Außerdem kam es durch das unausgeglichene 
RANKL/OPG-System zu einer erhöhten Osteklastenentwicklung in Sirt1-KO-OB. 
Aus all meinen Ergebnissen und in Anbetracht der vorangegangenen Daten 
sowie der neuesten Literatur kann folgendes Modell (s. Abb. 45) für die Rolle der 
Peroxisomen während der OB-Differenzierung erstellt werden: Peroxisomen 
tragen zur Aufrechterhaltung der Homöostase des Lipidmetabolismus sowie des 
zellulären Redox-Stresses bei. Die Peroxisomendysfunktion, die durch die 
Deletion der Peroxingene Pex11β und Pex13 induziert wird, löst erhöhten 
zellulären oxidativen Stress, Lipidtoxizität und mögliche Änderungen der 
Deacetylierungsfähigkeit von SIRT1 aus. Die Aktivitäten der 
Transkriptionsfaktoren PPAR, FoxO und RUNX2 werden wiederum durch 
oxidativen Stress und Lipidakkumulation induziert. Diese Induktion wird durch die 
Deacetylierung der oben genannten Transkriptionfaktoren mittels SIRT1 und der 
RA-Signalkaskade beeinflusst. Folglich könnte diese Beeinflussung zum Teil zu 
den gravierenden Veränderungen in der Differenzierung, der Apoptose, dem 
Zellzyklus und der Proliferation in OB, sowie während der Ossifikation in ZS-
Mäusen beitragen. 
 
Abbildung.45. Schematische Darstellung des angenommenen Mechanismus der 
Regulation der OB-Differenzierung durch Peroxisomen über die 
Deacetylierungsaktivität von SIRT1. Ox: oxidativer Stress; AC: Acetylierung.  
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9. Index of abbreviation  
 
ALP  Alkaline phosphatase 
ACOX  Acyl-CoA oxidase 
BMD  Bone Mineral Density  
BGLAP Bone γ-carboxyglutamic acid-containing protein  
°C  Degree Celcius 
CDKS  mitotic cyclin-dependent kinases 
COL1a1 collagen, type I, alpha 1 
COL1a2 collagen, type I, alpha 2 
CRABPII  retinoic acid binding protein II  
DHCA  dihydroxycholestanoic acid 
DHE  dihydroethidium 
DLP1  dynamin-like protein  
ER  Endoplasmic Reticulum 
ES  Embryonic Stem Cell 
FACS  Fluorescence-activated cell sorting 
FoxO  Forkhead box O  
g  gram 
H2-DCFDA dichlorodihydrofluorescein diacetate 
HO-1  Heme oxygenase 1 
4-HNE 4-hydroxynonenal  
IBSP  integrin-binding sialoprotein  
IF  immunofluorescence 
IRD  Infantile Refsum’s Disease  
KO  Knockout 
LEF  lymphoid Enhancer-Binding Factor. 
LRP  low density lipoprotein receptor-related protein  
M-CSF macrophage colony-stiumlating factor 
min  minute 
NAC  N-Acetyl-Cysteine 
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NALD  Neonatal Adrenoleukodystrophy  
NFATc1 nuclear factor of activated T cells cytoplasmic 1  
NRF2  Nuclear factor (erythroid-derived 2)-like 2 
OPN  Osteopontin 
OPG  osteoprotegerin  
Osx  Osterix  
PBD   Peroxisome Biogenesis Disorders 
PBS  Phosphate buffered saline 
PFA  Paraformaldehyde 
Pgc-1α  Proliferator-activated receptor γ-coactivator 1α 
PMP  Peroxisomal Membrane Protein 
PPARγ Peroxisome Proliferator-Activated Receptor-γ 
PP2A  protein phosphatase 2A 
PTS  Peroxisomal Targeting Sequences  
mPTS  Membrane Peroxisomal Targeting Sequences 
NF-B  nuclear factor B 
PBD  peroxisome biogenesis disorders 
PVDF  polyvinylidene fluoride 
RA  retinoic acid 
RAR  retinoic acid receptors  
RCF  relative centrifugal force 
RCPD  rhizomelic chondrodysplasia punctata 
ROS  Reactive oxygen species 
RT  Room temperature  
RT-PCR Semi-quantitative polymerase chain reaction 
RXR  Retinoid X receptor  
THCA  trihydroxycholestanoic acid 
PUFA  Polyunsaturated Fatty Acid 
RANK  receptor activator of NF-B 
RANKL receptor activator of NF-B ligand 
ROS  Reactive Oxygen Species  
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Runx2 runt-related transcription factor 2  
qPCR  Quantitative real time  polymerase chain reaction 
s  Second 
SH3  C-terminal Src homology domain 
SOD2  Manganese Superoxide dismutase 
RT-PCR Semi-quantitative polymerase chain reaction 
TCF  T-cell factor  
VLCFA Very Long Chain Fatty Acids 
WB  Western Blot  
WT  Wild Type 
ZS  Zellweger Syndrome  
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